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ABSTRACT 
The neural crest is a group of migratory, multipotent stem cells that play a crucial 
role in many aspects of embryonic development. This uniquely vertebrate cell population 
forms within the dorsal neural tube but then emigrates out and migrates long distances to 
different regions of the body. These cells contribute to formation of many structures such 
as the peripheral nervous system, craniofacial skeleton, and pigmentation of the skin. Why 
some neural tube cells undergo a change from neural to neural crest cell fate is unknown as 
is the timing of both onset and cessation of their emigration from the neural tube. In recent 
years, growing evidence supports an important role for epigenetic regulation as a new 
mechanism for controlling aspects of neural crest development. In this thesis, I dissect the 
roles of the de novo DNA methyltransferases (DNMTs) 3A and 3B in neural crest 
specification, migration and differentiation. First, I show that DNMT3A limits the spatial 
boundary between neural crest versus neural tube progenitors within the neuroepithelium. 
DNMT3A promotes neural crest specification by directly mediating repression of neural 
genes, like Sox2 and Sox3. Its knockdown causes ectopic Sox2 and Sox3 expression at the 
expense of neural crest territory. Thus, DNMT3A functions as a molecular switch, 
repressing neural to favor neural crest cell fate. Second, I find that DNMT3B restricts the 
temporal window during which the neural crest cells emigrate from the dorsal neural tube. 
Knockdown of DNMT3B causes an excess of neural crest emigration, by extending the 
time that the neural tube is competent to generate emigrating neural crest cells. In older 
embryos, this resulted in premature neuronal differentiation. Thus, DNMT3B regulates the 
duration of neural crest production by the neural tube and the timing of their differentiation. 
 vi 
My results in avian embryos suggest that de novo DNA methylation, exerted by both 
DNMT3A and DNMT3B, plays a dual role in neural crest development, with each 
individual paralogue apparently functioning during a distinct temporal window. The results 
suggest that de novo DNA methylation is a critical epigenetic mark used for cell fate 
restriction of progenitor cells during neural crest cell fate specification. Our discovery 
provides important insights into the mechanisms that determine whether a cell becomes 
part of the central nervous system or peripheral cell lineages.   
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Introduction 
   
Neural crest cells are a population of multipotent stem cells that are induced during 
gastrulation at the neural plate border, between the neural and non-neural ectoderm.  By 
neurulation, definitive neural crest cells are specified and initiate neural crest marker 
expression as premigratory cells within the dorsal neural tube. They then emerge from the 
neural tube by undergoing an epithelial to mesenchymal transition (EMT) whereby they 
delaminate from the neuroepithelium, assume a mesenchymal morphology and migrate 
extensively to different parts of the body (Figure1). After migration, they differentiate into 
numerous derivatives including neurons and glia of the peripheral nervous system, 
melanocytes, portions of the cardiac outflow tract, craniofacial bone and cartilage, and 
smooth muscle of major blood vessels (Sauka-Spengler and Bronner-Fraser 2008; Sauka-
Spengler and Bronner 2010; Bronner and LaBonne 2012). Understanding neural crest 
development is important because these cells are involved in a variety of birth defects, 
diseases and cancers such as cleft lip and palate, heart defects, Hirschprung’s disease, 
melanoma and neurofibromatosis.  
 
There is good evidence that transcriptional events are critical for many aspects of 
neural crest (NC) development. A neural crest gene regulatory network (GRN) 
(Meulemans and Bronner-Fraser 2004) comprised of transcriptional and signaling events 
has been proposed to function in a feed-forward series of regulatory circuits (Sauka-
Spengler and Bronner-Fraser 2006; Betancur et al. 2010). This neural crest GRN appears to 
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be highly conserved throughout vertebrates, including basal agnathans (Sauka-Spengler et 
al. 2007), suggesting that these regulatory mechanisms were in place more than 550 million 
years ago. However, the current formulation of the NC GRN is far from complete and it is 
becoming increasingly clear that additional inputs play critical roles in neural crest 
formation and migration. 
As one example, there is growing evidence to support roles for epigenetic inputs as 
critical for many aspects of neural crest development, most notably in controlling the 
timing of gene expression at different developmental stages. Below, I summarize the 
process of neural crest formation (Figure2) and discuss the role of epigenetic regulation 
during neural crest development, neural crest related birth defects and diseases.  
 
Neural crest induction 
 
The process of neural crest induction is mediated by signaling ligands including 
BMPs, Wnts and FGFs that are secreted from neighboring tissues such as the neural and 
non-neural ectoderm as well as the underlying mesoderm (Figure 1). During gastrulation, 
these signals establish the neural plate border region between the neural and non-neural 
ectoderm and initiate neural crest induction (Heeg-Truesdell and LaBonne 2004; Steventon 
et al. 2005; Basch and Bronner-Fraser 2006; Stuhlmiller and Garcia-Castro 2012). The 
neural plate border region has the competence to form not only neural crest cells but also 
other cell types within the central nervous system (CNS). Signaling inputs in this region 
up-regulate a group of transcription factors called ‘neural plate border specifier genes’ 
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including Msx1/2, Pax3/7, Dlx5, Gbx2 and Zic. The collective and overlapping expression 
of these genes confers upon the neural plate border region the unique ability to form neural 
crest cells.  
 
Neural crest specification  
 
During neurulation, neural plate border circuitry activates a set of transcription 
factors called the ‘neural crest specifier genes’ in the dorsal neural tube.  These include 
genes like AP2α, n-Myc, Id, Snail2, FoxD3, Ets-1, Sox8/ 9/10, with some differences in the 
timing of their initial expression. These factors function to control cell cycle, proliferation, 
and survival, while maintaining multipotency, initiating delamination, and promoting their 
epithelial-to-mesenchymal transition (EMT). A bona fide neural crest cell is first 
recognizable in the dorsal neural tube by its expression of transcription factors such as 
FoxD3, Sox9, Snail2, and Sox10. These genes regulate downstream effector genes to 
promote EMT and migration, at which point the neural crest cells become an identifiable 
population of multipotent migratory stem cells (Gammill and Bronner-Fraser 2003; 
Barembaum and Bronner-Fraser 2005; Sauka-Spengler and Bronner-Fraser 2008). 
 
Neural crest EMT and migration  
 
During the epithelial to mesenchymal transition process, neural crest cells alter cell 
junctions, adhesive properties and morphology to acquire cell motility, which enables them 
  
5 
to migrate long distances to their final destinations. For example, they switch from 
expression of Type I cadherins (characteristic of epithelial cells) to Type II cadherins (of 
mesenchymal character) and lose tight junctions while establishing gap junctions. Neural 
crest specifier genes like Snail2 and FoxD3 regulate downstream genes to facilitate this 
process. As a result, N-cad and Cad6B are down-regulated and Cad7 is up-regulated along 
with gap junction proteins and integrins (Kerosuo and Bronner-Fraser 2012; Strobl-
Mazzulla and Bronner 2012a). At this point, neural crest cells become a distinct group of 
mesenchymal cells that delaminate from the neuroepithelium and migrate out of the dorsal 
neural tube.  
 
During their migration, neural crest cells interact with each other and with their 
environment via signaling receptors such as Neuropilins, Robo and Ephrin receptors, which 
respond to ligands that guide them to specific destinations and facilitate their differentiation 
(Sauka-Spengler and Bronner-Fraser 2008; Betancur et al. 2010). 
 
At the end of migration, the expression of most neural crest specifier genes is 
down-regulated. However, expression of some factors like Sox10 and FoxD3 remain on in 
a subset of cells and contribute to terminal differentiation (Kelsh 2006). Depending on the 
axial location and time of emigration, neural crest cells give rise to a wide variety of 
derivatives such as peripheral neurons and glia, craniofacial skeleton, cartilage derivatives, 
and melanocytes. (Le Douarin 1982; Betancur et al. 2010). 
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 Signaling pathways utilized during neural crest EMT are common to many other 
developmental EMTs (Lim and Thiery 2012). Signaling molecules like TGF-	  β family, 
Wnt and FGF and transcription factors like Snail genes are common to EMTs during both 
gastrulation and neural crest cell emigration (Acloque et al. 2009). Not surprisingly, 
abnormal activation of EMT programs in carcinoma cells also utilizes similar mechanisms 
to delaminate from an epithelial tumor as those used by neural crest cells, and this process 
results in the formation of invasive migratory tumor cells (Strobl-Mazzulla and Bronner 
2012a). Key neural crest transcription factors such as Snail, Sip1, Twist are common 
regulators in both neural crest development and tumor progression. The recurrence of EMT 
in adult disease may reflect a reactivation of developmental programs functioning at the 
cellular level. Thus, an in-depth understanding of neural crest EMT may contribute to our 
understanding of cancer metastasis and help guide the design of anti-invasive drugs.   
 
Developmental defects, diseases and syndromes 
 
Many of the most common human birth defects are related to abnormal neural crest 
development. Neural crest malformation can lead to craniofacial defects like cleft lip and 
palate, heart septation defects, and agangliogenesis of the colon (Tennyson et al. 1986; 
Youn et al. 2003; Jiang et al. 2006). In addition, neural crest cells are involved in a variety 
of diseases and syndromes such as Hirschsprung’s disease (HSCR), Wardensburg 
syndrome (WS), CHARGE syndrome and Williams Syndrome (Inoue et al. 2002; Ahola et 
al. 2009; Yoshimura et al. 2009; Bajpai et al. 2010; Kim et al. 2011). Understanding the 
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normal mechanisms of neural crest development will contribute to the discovery of 
therapeutic treatments on birth defects, cancers, and other diseases associated with aberrant 
neural crest cells. 
 
Epigenetic regulation  
 
In addition to transcription factors and signaling proteins, epigenetic regulators play 
an essential role in controlling proper neural crest development. Epigenetic modifications 
are defined as mechanisms that regulate gene expression without altering the underlying 
sequence of DNA (Bernstein et al. 2007; Bird 2007). Epigenetic modifiers can alter 
chromatin structure and genome function through different processes such as DNA 
modifications or histone modifications, or can work as a complex to regulate higher-level 
chromatin conformation in an ATP-dependent manner. Depending on the specific type of 
regulator, the outcome can either lead to gene activation, in which the chromatin is relaxed 
and DNA is accessible to transcription factors, or to gene repression, where chromatin is 
tightly packed and inaccessible to transcriptional regulators.  
 
Epigenetic modifiers are key regulators of developmental events and aberrant 
epigenetic marks are associated with many types of cancers, and disease states (Portela and 
Esteller 2010). Different types of DNA and histone modifications and family members of 
chromatin remodeling complexes have been reviewed recently in (Liu and Xiao 2011). 
Here, we focus on various epigenetic regulators that have been shown to play a role in 
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neural crest development and neural crest related diseases. The epigenetic machinery falls 
into the following groups: DNA methylation, histone methylation, histone acetylation, 
ATP-dependent chromatin remodeling complex, and other regulators that work with the 
epigenetic machinery to regulate neural crest development. 
 
DNA methylation 
 
During development, epigenetic repression is used to shut down alternative 
pathways during cell type specification and lineage commitment (Cedar and Bergman 
2008). One common type of gene repression in mammalian cells occurs via DNA 
methylation. DNA methylation is one of the most important epigenetic mechanisms 
regulating many different events including gene expression, genome imprinting, 
inactivation of the silent X chromosome, and genome stability (Ooi et al. 2009). After 
fertilization, repressive parental DNA methylation is erased or gradually lost, reprograming 
the cells of the early embryo to enable reacquisition of pluripotency (Mayer et al. 2000). As 
development proceeds, new DNA methylation marks are established to gradually restrict 
the cell’s potential (Mayer et al. 2000; Reik 2007; Borgel et al. 2010). In mammalian cells, 
60-90% of the cytosines are methylated in the context of CpG dinucleotides or CpG islands 
(Gardiner-Garden and Frommer 1987) (Namihira et al. 2004).  This process is mediated by 
the family of DNA methyltransferases: DNMT1, DNMT2, DNMT3L, DNMT3A and 3B. 
These enzymes catalyze the transfer of a methyl group on Cytosine using AdoMet (S-
adenosyl-L-methionine) as a donor (Turek-Plewa and Jagodzinski 2005), thereby inhibiting 
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interaction of some proteins with DNA, while facilitating the binding of others 
(Prokhortchouk and Defossez 2008). 
 
The DNMTs can be categorized into two main groups with DNMT1 representing 
the maintenance methyltransferase and DNMT3A and 3B acting as de novo 
methyltransferases. DNMT1 preferably attacks the newly synthesized strand of DNA 
during chromatin replication, repairing and maintaining the pattern of methylation 
according to the parent strand (Chen and Li 2006). DNMT2 is a tRNA metyltransferase 
(Goll et al. 2006); its role in development has yet to be studied. The de novo 
methyltransferases (DNMT3s) are the major players in tissue specific regulation during 
development. They establish the initial CpG methylation pattern. They consist of two 
enzymatically active methyltransferases DNMT3A and DNMT3B and one regulatory 
factor DNMT3L that augments the function of DNMT3A (Jurkowska et al. 2011b; 
Siddique et al. 2012) and promotes the activity of both DNMT3A and 3B (Wienholz et al. 
2010). 
De novo DNMTs recognize CpG islands and newly methylate DNA by catalyzing 
the transfer of a methyl group to cytosine residues (Cheng and Blumenthal 2008). Such 
methylation of CpG sites in the promoter region of a gene is thought to inhibit gene 
expression, as shown in cancer and stem cells (Momparler and Bovenzi 2000; Miranda and 
Jones 2007; Suzuki and Bird 2008; Altun et al. 2010). DNMT3A (Jurkowska et al. 2011a) 
and its paralog DNMT3B have been shown to be vital for normal mammalian development 
and play important roles in disease (Jaenisch and Bird 2003; Linhart et al. 2007; Ehrlich et 
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al. 2008; Yan et al. 2011). For example, DNMT3A double knockout mice die several 
weeks after birth, and DNMT3B double knockout embryos have rostral neural tube defects 
and growth impairment (Okano et al. 1999), suggesting a neural crest related phenotype.  
 
In the chick embryo, DNMT3A is predominantly expressed in the neural crest 
territory and its loss of function results in down regulation/loss of neural crest specifier 
genes Sox10, Snail2, FoxD3, etc. and the expansion of neural genes Sox2 and Sox3 into 
the neural crest territory [this thesis and (Hu et al. 2012)]. Intriguingly, DNMT3A plays an 
early function in repressing the neural genes Sox2 and Sox3 in the presumptive neural crest 
region, and this down-regulation of neural genes in the dorsal neural fold is a prerequisite 
to activate neural crest specifier genes (Hu et al. 2012).  
 
Although classically thought to act as repressors, DNMTs can also function as 
activators in some cases. Whereas traditional DNMT3A promoter methylation represses 
transcription, DNMT3A non-promoter DNA methylation has been shown to facilitate 
transcription by antagonizing Polycomb repression (Wu et al. 2010). In addition, DNMT3A 
can act as a co-repressor. In episomal cell lines, DNMT3A binds histone deacetylases and 
is recruited by a sequence-specific repressor RP58 to silence transcription, independent of 
its de novo methylation function (Fuks et al. 2001). 
 
Mutations in human DNMT3B are found in ICF (immunodeficiency-centromeric 
instability-facial anomalies) syndrome, comprised of facial abnormalities such as widened 
  
11 
nasal bridge and hypotelorism, neurological dysfunction and other related defects (Ehrlich 
et al. 2008; Jin et al. 2008). These defects are consistent with an important role for 
DNMT3B in neural crest development. In zebrafish, DNMT3B and histone 
methyltransferase G9a cooperate to regulate neurogenesis through Lef1 and play a critical 
role in forming the precursors of craniofacial structures, brain and retina (Rai et al. 2010). 
In human embryonic stem cells, knockdown of DNMT3B accelerates neural and neural 
crest differentiation and increases the expression of neural crest specifier genes (Pax3, 
Pax7, FoxD3, Sox10 and Snail2). In addition, H3K27me3 and polycomb complex protein 
are reduced at the promoter regions of neural crest specifier genes upon knock-down of 
DNMT3B in hESCs (Martins-Taylor et al. 2012).  
 
DNMT3B expression is significantly up-regulated during neural crest induction in 
chicken embryos (Adams et al. 2008). In my recent unpublished work, I show that 
DNMT3B influences the ability of neural tube cells to produce emigrating neural crest cells 
(Hu et al., in preparation). Knock-down of DNMT3B in chick causes an excess of neural 
crest emigration and up-regulation of neural crest genes Sox10, Snail2 and FoxD3, 
consistent with the data from human embryonic stem cells. In older embryos, this results in 
precocious neuronal differentiation of the trigeminal ganglia (Hu et al., unpublished). In 
contrast to the human syndrome and stem cell studies, however, conditional knock-down of 
DNMT3B in the mouse neural crest using Wnt1- or Sox10-cre does not produce an 
apparent craniofacial phenotype (Jacques-Fricke et al. 2012). Wnt-1-Cre driven knock-out 
of DNMT3B exhibits only mild migration defects of dispersed Sox10 positive cells, that 
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recover during cranial gangliogenesis (Jacques-Fricke et al. 2012). This could reflect 
differences between species, or may indicate that the primary function of DNMT3B is in 
non-neural crest tissue.  
 
In addition to embryonic development, DNA methyltransferases are also thought to 
be involved in metastasis. Many tumor suppressor genes are silenced in a variety of human 
cancer cells by promoter methylation whereas some pro-oncogenic genes are activated by 
hypomethylation. In human prostate cancer cells, increased binding of DNMT3B to E-
cadherin (a tumor suppressor gene) promoter was detected. This leads to promoter 
hypermethylation, resulting in less cell aggregation and increased metastasis (Kwon et al. 
2010). In addition, DNMT1, 3A and 3B proteins have been detected in retinoblastomas 
whereas there are no DNMT proteins in normal retinas. Increased levels of DNMTs 
correlate with retinoblastoma tumorigenesis (Qu et al. 2010). Given that neural crest and 
cancer EMT and migration share many similar players and neural crest derived cells are 
prone to metastasis leading to neuroblastoma, melanoma, and neurofibroma, understanding 
how DNMTs regulate neural crest EMT and migration may also shed light on the 
mechanisms leading to cancer progression and metastasis.  
 
Histone modifications 
 
Histone proteins associate with compacting DNA strands and organize them into 
structural components called nucleosomes. Each nucleosome contains eight histones: two 
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of each of the core histones H2A, H2B, H3 and H4 form octameric structures called 
nucleosome cores around which DNA is wrapped with unstructured tails (Gibney and 
Nolan 2010). The core histone proteins are highly conserved throughout evolution and their 
tails are subject to post-translational modifications such as: methylation, acetylation, 
deacetylation, phosphorylation, ubiquitination, sumoylation, etc. (Berger 2007; Kouzarides 
2007). New histone marks and new types of histone modification continue to be discovered 
throughout time (Tan et al. 2011). Among these modifications, histone methylation and 
acetylation are, to date, the best studied in neural crest cells and they play an essential role 
in neural crest development.  
 
Histone methylation is associated with both active and repressive transcription 
(Kouzarides 2007). Histone methyltransferases add methylation while histone 
demethylases remove methylation marks. H3K4me3 (Histone 3 Lysine 4 trimethylation) 
established by Trithorax group proteins is indicative of transcriptionally permissive 
chromatin states, and is mostly found in the promoter regions of genes (Barski et al. 2007; 
Pan et al. 2007; Akkers et al. 2009; Cheung et al. 2010). H3K36me3 is associated with 
euchromatic regions that are associated with active transcription and is mostly found in 
gene bodies. In contrast, H3K27me3 catalyzed by Polycomb repressive complex (Schwartz 
et al. 2006; Tolhuis et al. 2006; Swigut and Wysocka 2007; Simon and Kingston 2009) and 
H3K9me3 (Nielsen et al. 2001; Shi et al. 2003; Allan et al. 2012) are associated with 
transcriptional repression.  
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Histone demethylases such as members of the Jumonji family revert histone 
methylation (Tan et al. 2008). In neural crest development, a histone demethylase of the 
Jumonji family JmjD2A (also known as KDM4A) is the first epigenetic gene discovered to 
regulate neural crest specification via modulating H3K9me3 of neural crest genes (Strobl-
Mazzulla et al. 2010). JmjD2A is expressed in the neural crest forming territory during 
neural crest specification and knocking down JmjD2A causes dramatic loss of neural crest 
specifier genes such as Sox10, Snail2, FoxD3, etc. In vivo ChIP assays reveal the direct 
interaction of JmjD2A with Sox10 and Snail2 promoter regions that are occupied with 
H3K9me3 (Strobl-Mazzulla et al. 2010). JmjD2A is required to demethylate Sox10 and 
Snail2 at the proper time and place to allow neural crest specification to occur.  
 
 Along similar lines, patients with mutations in the histone demethylase PHF8, a 
JmjC domain containing protein, have craniofacial deformities. PHF8 is capable of 
demethylating H4K20me1 and H3K9me1 around the transcription start site to activate 
transcription. In zebrafish, PHF8 directly regulates homeodomain transcription factor 
MsxB during cranial facial development especially in the lower jaw (Phillips et al. 2006; Qi 
et al. 2010). MsxB was previously implicated in regulation of neural crest development 
(Phillips et al. 2006).  
 
The Polycomb Repression Complex modifies chromatin to allow epigenetic 
silencing of genes through H3K27me3. Aebp2, a component of the Polycomb Repression 
Complex 2 (Kim et al. 2009), is expressed in the neural crest territory in mouse and 
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heterozygous mutants carry phenotypes similar to human patients with Hirschsprung’s 
disease (HSCR) and Waardensburg syndrome (WS), both diseases are caused by migratory 
and developmental defects in neural crest cells (Inoue et al. 2002; Ahola et al. 2009; Kim et 
al. 2011). Expression levels of key neural crest genes such as Sox10, Pax3 and Snail2 are 
elevated in these heterozyous mutants, further suggesting that Aebp2 misregulation is 
responsible for HSCR and WS through improper regulation of the neural crest genes (Kim 
et al. 2011).  
 
  
Histone acetylation is associated with active transcription and histone de-
acetylation silences transcription (Jenuwein and Allis 2001). HATs and HDACs are two 
classes of enzymes that antagonize each other (Shahbazian and Grunstein 2007). HATs 
(histone acetyltransferases) transfer acetyl groups to lysines, and their binding is correlated 
with active transcription (Carrozza et al. 2003; Shahbazian and Grunstein 2007). 
Acetylation neutralizes the charge of lysine residues and weakens their interactions with 
negatively charged DNA, thus allowing the chromatin structure to open up and increasing 
the accessibility of transcription factors (Ekwall 2005; Wang et al. 2009). HATs have also 
been identified as co-transcriptional activators (Roth et al. 2001; Yang 2004). In contrast, 
HDACs (histone deacetylases) de-acetylate lysine residues and one of their major functions 
is to remove acetyl groups added by HATs (Wang et al. 2002). As a result, chromatin is 
reset to its tightly packed state (Hsieh et al. 2004). As a consequence, HDACs have been 
identified as transcriptional co-repressors (Kadosh and Struhl 1997; Rundlett et al. 1998). 
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 Epigenetic annotation such as histone acetylation is closely associated with 
enhancer activity and is a new, powerful tool to identify neural crest cis-regulatory regions 
together with conserved regulatory regions. For example, H3K27ac is associated with 
active enhancers (Heintzman et al. 2009; Creyghton et al. 2010; Rada-Iglesias et al. 2011; 
Bonn et al. 2012; Cotney et al. 2012). In human neural crest cells derived from hESC, 
ChIP-seq against various histone marks reveals that active enhancer regions are enriched 
with H3K27ac and H3K4me1 while lacking H3K4me3 (Rada-Iglesias et al. 2012). Neural 
crest enhancer elements that are conserved between human and chicken are both enriched 
for H3K27ac. Many have now been identified as a result of these studies and it will be 
interesting to monitor their functional characterization. 
 
In neural crest development, the HDAC inhibitor Trichostatin A (TSA) promotes 
trunk neural crest cell specification (Murko et al. 2013). In chick, in ovo treatment with the 
inhibitor TSA induces neural crest markers Bmp4, Pax3, Sox9 and Sox10, and dysregulates 
the proper timing of cadherins expressions such as Cad6B and N-cad. As a result, there is 
premature loss of epithelial characteristics.  
 
The HDAC repression complex plays an essential role in regulating neural crest 
migration. Premigratory neural crest cells from the dorsal neural tube undergo an epithelial 
to mesenchymal transition to gain migratory properties and travel to distant parts of the 
body. The transcriptional repressor Snail2 has been reported to directly repress the 
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adhesion molecule Cadherin6B in premigratory neural crest cells (Hatta et al. 1987; 
Nakagawa and Takeichi 1995; Taneyhill et al. 2007). Epigenetic regulation has been shown 
to play a critical underlying molecular role in this repression (Strobl-Mazzulla and Bronner, 
2012). Interaction between an adaptor protein, PHD12, and Snail2 makes it possible to 
recruit the repressive complex Sin3A/HDAC to the Cad6B promoter region.  As a result, 
Cad6B transcription is repressed via histone deacetylation. The dual specificity of 
epigenetic regulators such as PHD12 and transcription factors such as Snail2 are required 
to cooperatively regulate the process of neural crest EMT (Strobl-Mazzulla and Bronner 
2012b). 
 
 HDACs play important roles in regulating downstream neural crest differentiation 
as well. HDAC1 mutant zebrafish embryos exhibit a severe reduction in the number of 
melanoblast expressing MITFa (a critical transcription factor for melanoblast development) 
and retain prolonged FoxD3 expression in neural crest cells. FoxD3 physically interacts 
with the MITFa promoter and reducing FoxD3 expression in HDAC1 mutants partially 
rescues the melanoblast defects. Thus, during normal melanogenesis, HDAC1 is required 
to repress FoxD3 expression which in turn de-represses MITFa to allow melanophore 
specification, migration and differentiation (Ignatius et al. 2008).  
 
 In another example, HDAC3 is crucial for the regulation of smooth muscle 
differentiation and cardiac outflow tract formation during cardiac neural crest development 
in mouse (Singh et al. 2011). Similarly, during cranial neural crest differentiation into the 
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skull, conditional deletion of HDAC8 driven by Wnt1-Cre in mice results in loss of 
specific cranial skeletal elements. HDAC8 epigenetically controls skull morphogenesis in 
neural crest-derived cells by repressing homeobox transcription factors Otx2 and Lhx1 
(Haberland et al. 2009).  
 
 In zebrafish craniofacial morphogenesis, embryos treated with HDAC4 morpholino 
exhibit loss of cranial neural crest derived palatal skeletal precursor cells and this later 
results in defects in the developing palate including cleft plate and a shortened face 
(DeLaurier et al. 2012). In human development, HDAC4 is also highly associated with 
neural crest related diseases and syndromes. Haploinsufficiency of HDAC4 is associated 
with brachydactyly mental retardation syndrome with features such as craniofacial and 
skeletal abnormalities (Williams et al. 2010). In addition, high throughput SNP analysis has 
linked HDAC4 with nonsyndromic oral clefts, a common birth defect closely related to 
neural crest development (Park et al. 2006). Moreover, infants exposed to the drug valproic 
acid (VPA) (an HDAC inhibitor) during pregnancy have an increased risk of neural crest 
and neural tube related malformations including cleft lip and palate, and cardiovascular 
defects (Alsdorf and Wyszynski 2005; Wyszynski et al. 2005). 
 
 In summary, HDACs execute important functions in the control of both enhancer 
activity and promoter regions of transcription factors to regulate gene expression. Their 
activity affects numerous aspects of neural crest development ranging from specification to 
migration and differentiation.  
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ATP-dependent chromatin remodelers 
 
 The ATP-dependent chromatin remodeling complexes such as SWI/SNF, ISWI, 
and CHD regulate gene expression by changing the position or structures of higher order 
chromatin in an ATP-dependent manner. They create nucleosome-free regions to facilitate 
access of DNA to transcription factors and regulatory proteins (Kwon and Wagner 2007; 
Wu et al. 2009). CHD7, an ATP-dependent chromatin domain helicase DNA-binding 
domain member, cooperates with PBAF (SWI/SNF chromatin remodeling complex 
(Muchardt and Yaniv 2001)) to promote neural crest specification in hESC induced neural 
crest cells. CHD7 activates core neural crest transcriptional circuitry including Sox9 and 
Twist through directly regulating the enhancer regions of these genes (Bajpai et al. 2010). 
Sixty-seven percent of CHARGE syndrome (a rare genetic disorder) patients have CHD7 
mutations (Zentner et al. 2010). CHD7 impairment in Xenopus embryos recapitulates 
major CHARGE syndrome features such as craniofacial malformations, peripheral nervous 
system abnormalities and heart defects (Bajpai et al. 2010). Consistent with this, CHD7 
deficient mice exhibit craniofacial abnormalities (Bosman et al. 2005; Hurd et al. 2007; 
Layman et al. 2009). Taken together, these data suggest that CHARGE syndrome is a result 
of CHD7 malfunction in early neural crest development. In addition, in zebrafish, Brg1, a 
member of the SWI/SNF chromatin-remodeling complex, plays an important role in neural 
crest induction, possibly via regulating the promoter region of Snail2 (Eroglu et al. 2006).  
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WSFT, Williams syndrome transcription factor, is a major subunit for two distinct 
ATP-dependent chromatin remodeling complexes: WINAC and WICH. It is one of the 
genes associated with Williams syndrome, a developmental disorder in which patients have 
problems in neural crest derived tissues. These include facial abnormalities, heart defects, 
and neural problems, among other defects. In Xenopus embryos, WSFT is expressed in the 
migratory neural crest and branchial arches. Knock-down of WSFT perturbs Snail and 
Snail2 expression in the branchial arches. There are severe defects in neural crest migration 
and maintenance, whereas neural crest induction is unaffected (Barnett et al. 2012). In mice, 
WSFT heterozygous mutants have cardiovascular abnormalities that phenocopy Williams 
syndrome patients (Yoshimura et al. 2009). Taken together, these data suggest that 
malfunction of WSFT during neural crest development is a major contributor to Williams 
syndrome.   
Other epigenetic regulators 
 
The reduced folate carrier (RFC) is a membrane-bound receptor involved in folate 
uptake by cells. Mice lacking RFC1 develop multiple defects including neural tube, 
craniofacial and heart abnormalities (Gelineau-van Waes et al. 2008). In Xenopus, XRFC is 
expressed exclusively in the neural crest domain and its morpholino-mediated knockdown 
down-regulates neural crest markers such as Zic1, Snail2, and FoxD3 (Li et al. 2011). As a 
result, Twist1 positive neural crest cells fail to migrate ventrally and embryos exhibit 
similar phenotypes to those observed in mice. In animal cap assays, knock-down of RFC 
reduces the levels of H3K4me1 and H3K4me3. Over expressing lysine transferase hMLL1 
  
21 
in XRFC MO treated embryos fully rescues Zic1 and FoxD3 expression and partially 
rescues Snail2 and Twist1 expression (Li et al. 2011). Taken together, these data suggest 
that an RFC mediated folate metabolic pathway controls neural crest development through 
epigenetic mechanisms. 
 
Leo1 is a component of the Polymerase-Associated Factor (PAF1) complex 
associated with chromatin remodeling and gene regulation (Krogan et al. 2003; Simic et al. 
2003; He et al. 2004).  In zebrafish mutants with truncated Leo1 protein, there is reduced 
expression of Crestin, Gch2, and Miftfa in neural crest derived cells (Nguyen et al. 2010). 
As a consequence, mutants have phenotypes such as reduced numbers of melanocyte, 
craniofacial cartilage, and glial cells. It is interesting to speculate that Leo 1 may be 
essential for neural crest differentiation, possibly through epigenetic regulations.  
 
Perspective and overview 
 
It is now clear that, in addition to transcriptional regulators, epigenetic modifiers 
serve as important inputs that are crucial for proper neural crest development. At a given 
time point, epigenetic modifiers control aspects of neural crest development in a spatially 
and temporally specific manner. They are capable of communicating at both the promoter 
and enhancer regions to render DNA in an accessible state for transcription, poise an 
enhancer region for future activation, or remove active marks to turn off transcription. 
Furthermore, these regulators cross-talk and work together to achieve their goals. For 
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example, DNA methyltransferases often work with histone methyltransferases to shut 
down alternative pathways and histone demethylases read and remove repressive marks 
and work along with acetylases to activate transcription at the appropriate time. Each cell 
lineage is marked with different combinations of epigenetic modifications at a given 
developmental time point. Uncovering these marks in neural crest cells will be critical for 
understanding both neural crest development and related diseases.  
 
In the remaining chapters, I elaborate on my research discoveries in avian embryos 
to demonstrate the necessity of de novo DNA methylation in neural crest specification and 
the neural crest epithelial to mesenchymal transition (EMT). Neural crest precursors 
initially reside within the dorsal neural tube and they subsequently segregate and emigrate 
out of the neural tube to become a distinct stem cell population. The molecular mechanisms 
underlying the neural tube to neural crest transition are a long-standing mystery. In Chapter 
2, I show that the DNA methyltransferase, DNMT3A, promotes neural crest cell 
specification by directly mediating repression of the neural genes. DNMT3A plays a 
critical function in the neural versus neural crest cell fate decision. Shortly after their overt 
specification, neural crest cells undergo a process of EMT that allows them to emigrate out 
of the dorsal neural tube and migrate extensively to different parts of the body. In chick, 
neural crest EMT occurs over a defined period of approximately one day.  Little is known 
about the mechanisms that end EMT and limit the ability of the CNS to produce neural 
crest. In Chapter 3, I show that DNMT3B influences the ability of neural tube cells to 
produce emigrating neural crest cells. The results show that it is required for the proper 
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timing of cessation of neural crest emigration from the dorsal neural tube at cranial levels. 
Taken together, the data show that DNA methylation plays a dual role in neural crest 
development with each DNMT paralogue primarily functioning during distinct temporal 
window.  
 
Chick as a research model system 
 
 Most scientists who study the functions of DNMTs use stem cells that can be 
maintained in culture under artificial conditions and obtained in large quantities for 
biochemical analysis. In contrast, we are studying events that occur in living embryos in 
order to understand the mechanism of DNMTs in their endogenous environment. To do so, 
we have adapted chick embryos as a research model to study the in vivo functions of 
DNMTs.  
 
 Chick embryos have many advantages for characterizing developmental events. 
Birds like humans are amniotes, but develop outside the mother in a morphologically 
similar manner to human embryos at comparable stages. Thus, they are easily accessible to 
experimental manipulations at early developmental stages, allowing temporally and 
spatially controlled genetic perturbations. For example, we can perform electroporations in 
half embryos or half neural tubes throughout early stages, leaving the other half as an 
internal control. Thus, we can compare the effects of protein knockdown using 
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morpholinos on the experimental versus control side of the same embryo, eliminating 
differences due to stage variation and allowing us to characterize phenotypes accurately.  
 
 In addition, we have adapted cell biological protocols to the chick system so that 
reasonably small amounts of cells can be used to perform biochemistry and high 
throughput analysis. For example, we can dissect small amounts of tissue for micro-
Chromatin Immunoprecipitation analysis to verify direct interactions between proteins and 
DNA in vivo, and NanoString technology to evaluate the loss of function effects on 
hundreds of genes simultaneously from samples of a single embryo.  
 
 Moreover, several neural crest enhancers are functional in chick, which allows us to 
perform ectopic expression of constructs specifically in the neural crest cells for 
overexpression or rescue experiments. By electroporating enhancer regions mediating GFP 
expression, it is possible to use FACS to isolate pure neural crest cells for biochemistry 
analysis. 
 
 In the remaining chapters of my thesis, I use chick as a model system to 
characterize the roles of DNMT3A and 3B in neural crest specification and EMT.  
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Figure1. An overview of neural crest development 
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Figure1. An overview of neural crest development from (Sauka-Spengler and Bronner 
2010). This diagram summarizes key regulatory events involved in neural crest formation, 
migration, and differentiation during vertebrate development. 
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Figure 2. Regulatory steps in neural crest formation 
 
 
 
Figure 2. Regulatory steps in neural formation from (Sauka-Spengler and Bronner-Fraser 
2008). Signals such as FGF, Wnt, and BMP induce neural crest at the neural plate border 
and turn on neural plate border specifiers such as Pax3 and Zic1. Pax3 and Zic1 in turn act 
synergistically to up-regulate neural crest specifiers such as Snail and FoxD3. During this 
stage, neural crest cells go through cell cycle control, multipotency maintenance, and 
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delaminate from the dorsal neural tube. Neural crest specifiers such as Sox10 and FoxD3 
persist in delaminating neural crest cells and control expression of downstream effector 
genes such as Cadherin-7, matrix metalloprotease-10, integrins, neuropilins, and other 
transmembrane receptors (Sauka-Spengler and Bronner 2008).  
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Table 1. Summary of epigenetic regulation in neural crest development 
St. of NC 
Development 
Gene 
Name Epigenetic Mark 
 On/ 
Off   Targets Notes 
Neural Crest 
Specification DNMT3A 
DNA methylation 
targeting CpG 
islands OFF 
Sox2/3, 
SoxE, 
Snail2, 
FoxD3 
neural to neural 
crest transition 
  JmjD2A 
histone 
deacetylase 
targeting 
H3K9me3 ON 
Sox10, 
Snail2 
neural crest 
specification 
  CHD7 
ATP-dependent 
chromatin 
remodeler ON 
Sox9, 
Twist 
neural crest 
specification, 
CHARGE 
syndrome 
  Brg1 
chromatin 
remodeler ON Snail2 
neural crest 
induction 
  TSA HDAC inhibitor ON 
Bmp4, 
Pax3, 
Sox9, 
Sox10 
trunk crest 
specification 
Neural Crest 
EMT and 
migration PHD12 
histone 
deacetylase 
complex member OFF Cad6B 
neural crest 
EMT 
  HDAC8   OFF   facial skeleton 
  DNMT3B 
DNA methylation 
targeting CpG 
islands OFF 
Sox10, 
Snail2, 
FoxD3 
timing of neural 
crest emigration 
  RFC 
co-factor of hMLL1 
lysine transferase 
targeting H3K4me ON 
Zic1, 
Snail2, 
FoxD3 
dorsal to ventral 
migration 
Neural Crest 
Differentiation PHF8 
histone 
demethylase 
targeting 
H4K20me1 and 
H3K9me1 ON MSXB 
cranial facial 
jaw 
development 
  HDAC1 
removes 
acetylation OFF 
FoxD3, 
MITFa 
melanoblast 
development 
  HDAC3 
removes 
acetylation OFF   
smooth muscle 
and cardiac 
outflow tract 
  HDAC8 
removes 
acetylation OFF Otx2, Lhx1 
cranial 
differentiation 
into skull 
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  DNMT3B DNA methylation  OFF Lef1 
craniofacial 
structures, brain 
and retina 
development  
  HDAC4 
removes 
acetylation OFF   
palatal skeleton 
formation 
  G9a 
histone 
methylation OFF Lef1 
craniofacial 
structures, brain 
and retina 
development  
  VPA HDAC inhibitor ON   
neural tube 
defects, cleft lip 
and palate, and 
cardiovascular 
defects 
Syndromes 
and diseases WSTF 
ATP-dependent 
chromatin 
remodeler ON 
Snail, 
Snail2 
Williams 
syndrome 
  Aebp2 
Polycomb 
repression 
associated with 
H3K27me3 OFF 
Sox10, 
Pax3, 
Snail2 
Hirschsprung's 
disease and 
Warrensburg 
syndrome 
  HDAC4 
removes 
acetylation OFF   
brachydactyly 
mental 
retardation 
syndrome, oral 
clefts 
 
Table 1. Summary of epigenetic regulators in neural crest specification, EMT, migration, 
differentiation, and neural crest related diseases and syndromes. ON/OFF column indicates 
whether the epigenetic regulator acts to turn the transcription of its target gene(s) on or off. 
Targets column represents direct and/or indirect downstream targets. Notes column 
characterizes the specific timing during neural crest development, specific neural crest 
derived structures, and diseases/defects that the regulator is known to play a role in. Stage 
(St.) Neural Crest (NC) 
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Abstract 
 
The neural crest is an important embryonic stem cell type that forms much of the 
peripheral nervous system, facial skeleton and pigmentation of the vertebrate body. 
Originating within the dorsal neural tube, the events that cause neural crest cells to 
segregate from a central nervous system fate are unknown. Here, we show that DNA 
methyltransferase 3A (DNMT3A) promotes neural crest cell specification by directly 
mediating repression of the neural genes, Sox2 and Sox3. DNMT3A is expressed in the 
newly induced neural plate border region from which neural crest cells originate.  Its loss of 
function at the border leads to ectopic upregulation of Sox2 and Sox3 in the dorsal neural 
tube at the expense of neural crest markers, in a cell autonomous manner. In vivo 
Chromatin immunoprecipitation of neural folds further demonstrates that DNMT3A 
specifically associates with CpG islands in the Sox2 and Sox3 promoter regions, resulting 
in methylation leading to their repression.  The results suggest that DNMT3A functions in 
the embryo as a molecular switch between central nervous system versus peripheral cell 
lineages, repressing neural to favor neural crest cell fate.   
 
 
Introduction 
 
During development, neural crest stem cells contribute to many uniquely vertebrate 
derivatives, including peripheral ganglia and the craniofacial skeleton (Le Douarin 1982). 
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Although neural crest precursors initially reside within the neural tube, they subsequently 
segregate from other neuroepithelial cells by a heretofore unknown mechanism.  Whereas 
the remainder of the neural tube will form the central nervous system (CNS), neural crest 
cells undergo an epithelial to mesenchymal transition, emigrate from the CNS and migrate 
into the periphery. Single cell lineage analysis has shown that individual cells within the 
dorsal neural tube can contribute to both the CNS and neural crest (Bronner-Fraser and 
Fraser 1988) suggesting that premigratory dorsal neural tube cells are not yet committed to 
a neural crest fate.  Subsequently, a subpopulation of dorsal neural tube cells produces bona 
fide neural crest cells that migrate extensively to populate diverse derivatives, ranging from 
peripheral neurons to craniofacial cartilage and melanocytes. The molecular mechanisms 
underlying the neural tube to neural crest transition are a long-standing mystery.  In this 
study, we have explored the possibility that silencing via promoter DNA methylation may 
play a role in this cell fate choice during embryonic development.  
 
De novo DNA methyltransferases recognize CpG islands and newly methylate 
DNA by catalyzing transfer of a methyl group to cytosine residues (Cheng and Blumenthal 
2008). In cancer and stem cells, when such CpG island methylation occurs in the promoter 
region, gene expression is inhibited ((Momparler and Bovenzi 2000; Miranda and Jones 
2007; Altun et al. 2010).  De novo DNA methyltransferases, DNMT3A (Jurkowska et al. 
2011a) and DNMT3B, are vital for normal mammalian development and have been 
implicated in disease (Linhart et al. 2007; Ehrlich et al. 2008; Yan et al. 2011). For 
example, DNMT3A -/- mice die several weeks after birth and DNMT3B -/- embryos have 
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rostral neural tube defects and growth impairment(Okano et al. 1999). Moreover, 
mutations in human DNMT3B result in immunodeficiency-centromeric instability-facial 
anomalies syndrome, in which patients exhibit craniofacial abnormalities (Jin et al. 2008), 
suggesting a defect in neural crest development. By contrast, the function of DNMT3A in 
early development is not understood.  Here, we show that DNMT3A plays a critical 
function in de novo methylation during early nervous system and neural crest development.  
 
Results and Discussion 
 
Expression pattern of DNMT3A in the early chick embryo 
 
As a first step in analyzing its possible function, we examined the expression 
pattern of DNMT3A transcripts by in situ hybridization.  Intriguingly, DNMT3A is highly 
expressed at the neural plate border at gastrula stages, contrasting with low levels in the 
neural plate (Fig. 1A, st.5-7). Subsequently, transcripts are confined to the neural folds 
containing premigratory neural crest precursors (Fig. 1A, st.9), and later in migrating neural 
crest cells, labeled with HNK-1 antibody (Fig. S1A).  Thus, at early developmental stages, 
DNMT3A is selectively expressed in tissues associated with neural crest and early neural 
tube development.  
 
Knock-down of DNMT3A blocks neural crest specification, as assayed by FoxD3 
expression, in a cell autonomous manner 
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 To test the functional consequences of loss of DNMT3A during neural crest 
specification, we designed two different fluorescein tagged translation blocking antisense 
morpholino oligonucleotides (MO) targeted against DNMT3A.  These were electroporated 
into one half of the early chick embryo at gastrulation stages 4/5, with the uninjected side 
serving as an internal control. To verify that the knock-down was effective, we performed 
Western blots comparing protein levels in the electroporated side versus control half of the 
same embryo and found that a band corresponding to DNMT3A protein was significantly 
decreased in the presence of DNMT3A MO (Fig. 1B). We examined the effects of loss of 
DNMT3A on expression of FoxD3, as it is one of the earliest neural crest markers to 
appear in the dorsal neural tube.  FoxD3 was dramatically down-regulated after loss of 
DNMT3A on the morpholino-electroporated side of the embryo (Fig. 1C, D), in an 
apparently dose-dependent fashion as the severity of the phenotype increased with the 
amount of morpholino introduced (Fig. S1B).  
 
To control for the specificity of action of DNMT3A morpholino and demonstrate 
that the observed phenotype was not due to off-target binding, we co-electroporated 
DNMT3A MO with a construct encoding exogenous DNMT3A under the control of a 
cranial FoxD3 enhancer, NC1, which turns on at early St.8. This enhancer drives 
exogenous DNMT3A only in premigratory cranial neural crest cells. Despite the fact that 
the morpholino was introduced much earlier, this resulted in marked rescue of the loss-of-
function phenotype, restoring FoxD3 expression (Fig. 2A, B).  To examine whether the 
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catalytic activity of DNMT3A was important for its function, we co-electroporated 
DNMT3A morpholino and a rescue construct in which the catalytic domains of DNMT3A 
were removed.  Under identical co-electroporation conditions as above, this mutated form 
of DNMT3A failed to rescue the loss-of-function phenotype (Fig. S2A, B). This 
demonstrates that catalytic activity is critical for DNMT3A function during neural crest 
development.  
 
Although we hypothesize that DNMT3A acts in a cell autonomous fashion in the 
presumptive neural crest cells, it is possible that aberrant interactions between neural crest 
precursors and more ventral neural tube cells results in a neural crest phenotype. DNMT3A 
is expressed at high levels at the neural plate border, neural folds and premigratory neural 
crest, but is also expressed in the neural tube, albeit at much lower levels.  To test if the 
function of DNMT3A is cell autonomous, we compared its effect on the neural crest versus 
the rest of the neural tube.  Because we cannot selectively target the neural crest region in a 
predictable fashion, we electroporated the morpholino into the entire neural tube on one 
side of each embryo, and the neural tube with the exception of the dorsal neural fold region 
on the opposite side.  In 100% of cases, we noted that down-regulation of FoxD3 only 
occurred when DNTM3A protein was down-regulated in the presumptive neural crest itself 
(Fig. 2C). The finding that FoxD3 is absent from cells containing DNMT3A MO but 
present in cells lacking DNMT3A MO in the dorsal neural fold region, definitively 
demonstrates that DNMT3A acts cell autonomously (Fig. S2D). 
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Multiplex analysis reveals that loss of DNMT3A up-regulates neural genes, while 
down-regulating neural crest specifier genes 
 
In order to understand global and multiplexed changes in gene expression caused 
by DNMT3A knock-down, we performed NanoString analysis to monitor and quantify 73 
transcripts including genes expressed in the neural crest, neural tube, neural plate, neural 
plate border, placodes, nonneural ectoderm, and those involved in cell proliferation and cell 
death. Each DNMT3A knockdown embryo was analyzed at late St.8, by comparing the 
morpholino electroporated side to the uninjected side of the same embryo.  Because 
DNMTs are thought to inhibit transcription by methylating the promoter region of target 
genes, we were particularly interested in genes that were up-regulated as a consequence of 
down-regulating DNMT3A, as these represent potential direct targets.  Interestingly, the 
results show that transcriptional regulators characteristic of neural fate specification, Sox2 
and Sox3, as well as the neural plate border gene, Zic1, some EMT and placode related 
genes were upregulated after DNMT3A knock-down (Fig. 3A, Fig. S3A, B, C). 
 
 Sox2 (Pevny and Lovell-Badge 1997; Graham et al. 2003) was of particular 
interest since its misexpression in the neural folds blocks expression of the neural crest 
gene, Snail2 (Wakamatsu et al. 2004). Furthermore, Sox2 is a well-known pluripotency 
gene and is one of the four genes necessary to reprogram somatic cells into pluripotent 
stem cells (Pawlak and Jaenisch 2011). Therefore, we used in situ hybridization to verify 
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the upregulation of Sox2 noted by NanoString analysis. The results show that loss of 
DNMT3A causes expansion of Sox2 into the neural crest territory whereas, on the control 
side of the same embryo, Sox2 is absent from the neural crest domain (Fig. 3B).  
Interestingly, this is accompanied by changes in morphology of the dorsal neural tube, 
which appears less broad and more neuroepithelial than the control side.  In contrast to 
Sox2, the pluripotency genes, Nanog and Oct4/PouV, exhibited little or no expression in 
the cranial neural tube (Canon et al. 2006); and unpublished observation).  Moreover, their 
expression was unchanged after DNMT3A knock-down (data not shown). 
 
Sox2 and Sox3 are paralogues with overlapping function.  Therefore, we examined 
the effects of DNMT3A knock-down on Sox3 expression and found that, like Sox2, it is 
upregulated in the dorsal neural tube after morpholino knock-down (Figure 3B).  Thus, 
both genes are affected similarly, though Sox2 comes on earlier than Sox3 and appears to 
be the dominant neural specifier.  Like Sox2 and Sox3, Zic1 also was upregulated in the 
dorsal neural tube after loss of DNMT3A (Fig. 3B).    
 
Concomitant with up-regulation of Sox2, neural crest specification markers were 
down-regulated in DNMT3A knockdown embryos as shown in our NanoString data (Fig. 
3A).  This was verified by in situ hybridization for other neural crest specifiers and dorsal 
neural tube genes, including Sox9, Sox10, Snail2, Ets1, Wnt1, and N-Myc.  Like FoxD3, 
all of these appeared to be down-regulated upon loss of DNMT3A (Fig. 4).  Given that Wnt 
signaling has been implicated in neural crest specification and Wnt1 was down-regulated 
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after DNMT3A knock-down, we tested whether activated b-catenin could rescue the 
DNMT3A morpholino phenotype.  However, the results show no change in FoxD3 
expression (Fig. S4A, B).  
 
Co-immunostaining of Sox2 and FoxD3 in a single embryo treated with DNMT3A 
MO further demonstrates that loss of DNMT3A up-regulates neural genes such as Sox2, 
while down-regulating neural crest specifier genes such as FoxD3 (Fig. 3C, Fig. S3E).  We 
noted no significant change in cell death as shown by Casp-3 staining (Fig. S4C).  In 
addition, there was no change in expression of neural plate border genes like Msx1 and 
BMP4 in the dorsal neural tube (Fig. S4D).  
 
 To demonstrate a direct link between Sox2 upregulation and the reduction of 
neural crest gene expression, we electroporated a construct containing avian Sox2 
(Wakamatsu et al. 2004) into stage 4-5 neural plate, resulting in over-expression 
throughout the neural tube including ectopic expression in the dorsal region.  Consistent 
with our findings after DNMT3A knock-down, this caused down-regulation of the neural 
crest specifier genes FoxD3, Sox10, and Snail2 (Fig. S5).  For the reciprocal experiment, 
we examined whether morpholino knock-down of Sox2 and/or Sox3 was sufficient to 
induce neural crest cell fate in the neural tube. Loss of Sox2, Sox3 or both in combination 
failed to convert neural tube to neural crest cells.  However, these factors are critical for 
normal neural induction and their loss, as expected, led to severe neural defects. 
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 Neural specifier genes Sox2 and Sox3 are direct targets of DNMT3A 
 
 The Nanostring and in situ data raise the intriguing possibility that de novo 
methylation of the Sox2 promoter region by DNMT3A may be essential for repression of 
the Sox2 in the dorsal neural folds, and necessary for the switch in its identity from neural 
to neural crest. To test this in the in vivo context, we used Chromatin Immunoprecipitation 
(ChIP) followed by qPCR to assess whether Sox2 is a direct target of DNMT3A. To this 
end, dorsal neural folds were dissected from stage 8 embryos and processed for microChIP 
as previously described (Betancur et al. 2010; Strobl-Mazzulla et al. 2010). The data show 
that DNMT3A associates with the Sox2 promoter region, but not with the N2 enhancer 
region of Sox2 (Uchikawa et al. 2003)(Fig. 5).  Similar to Sox2, ChIP analysis shows that 
DNMT3A also occupies the promoter region of Sox3, the paralogue of Sox2 (Fig. 5).  In 
contrast, Zic1, which was also upregulated after DNMT3A knock-down, does not appear to 
be a direct target of DNMT3A, since ChIP analysis failed to show binding at its promoter 
region (data not shown).    
 
 We further examined the methylation pattern of Sox2 and Sox3 in the dorsal neural 
tube of stage 8.  As expected, the results show that both Sox2 and Sox3 are methylated in 
the vicinity of their promoters (Fig. S2C). Taken together, these findings definitively show 
that DNMT3A directly binds to the promoter regions of Sox genes and represses their 
transcription via methylation, thus allowing the acquisition of neural crest gene expression.   
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Our data show that DNA methylation acts as a molecular switch to turn off neural 
tube transcription factors, thus facilitating neural crest gene expression and fate acquisition. 
Previous studies on the molecular mechanisms of DNMT3A function have been focused on 
hematopoietic, neural stem cells and glioma cells in tissue culture.  These studies using in 
vitro data show that DNMT3A can promote cell differentiation by repressing pluripotency 
genes (Trowbridge and Orkin 2012). Consistent with this, our results in the developing 
embryo demonstrate that DNMT3A promotes neural crest cell type specification in an in 
vivo context by repressing neural genes like Sox2 and Sox3.  Although the mechanism by 
which DNMT3A is recruited to the promoter region of target genes is unknown, it has been 
shown to interact with numerous factors on transcription factor arrays (Hervouet et al. 
2009). Although these have yet to be validated, particularly in vivo, this list includes some 
neural plate border and neural crest specifier genes like Msx1, tfAP2a, Id2 and Myc.  Thus, 
it is intriguing to speculate that DNMT3A may be recruited to the Sox2 promoter by some 
of these factors that are selectively expressed in the neural crest forming domain.   
 
In some cases, de novo methyltransferases can also mediate methylation-
independent gene repression, by co-localizing with heterochromatin and associating with 
HP1 and MeCBP (methyl-CpG-binding protein). For example, in zebrafish neurogenesis, 
DNMT3B cooperates with histone methyltransferase G9a to inhibit expression of Lef1 (Rai 
et al. 2010).  Thus, it is particularly interesting that, in the neural folds, DNMT3A acts via 
regulation of the promoter region rather than the enhancer region as demonstrated by our 
ChIP data. This shows that, in addition to cis-regulatory events, epigenetic influences are a 
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critical mechanism for regulating transcription. Our discovery that DNA methylation 
promotes neural crest specification at the expense of neural tube identity provides 
important insights into the mechanisms that determine whether a cell becomes part of the 
central nervous system or peripheral nervous system.   
 
Materials and methods  
 
Embryos 
Fertilized chicken eggs were incubated at 37°C to desired stages.  
 
In situ hybridization 
Embryos were fixed with 4%paraformaldehyde, washed with PBS/0.1%Tween, dehydrated 
in MeOH, and stored at -20°C. Whole mount in situ hybridization was performed as 
described (Wilkinson 1992; Acloque et al. 2008). Dioxigenin-labeled RNA probes were 
made from DNA plasmids or ESTs of DNMT3A, Sox2, Sox9, Sox10, Snail2, FoxD3, 
Wnt1, Ets1, Nmyc, Msx1, and Bmp4. Embryos were sectioned at 16-18µm.  
 
Electroporation  
Embryos were electroporated at St.4-5 as described (Sauka-Spengler and Barembaum 
2008)  using DNMT3AMO1 (over ATG codon): TGGGTGTGTCACTGC TTTCCACCAT 
and/or DNMT3AMO2 (95 nucleotides upstream ATG): 
CAGTGTCCCCACGGCGCTTCCTGCT.  The rescue construct included the coding 
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region of DNMT3A (NM001024832.1) under control of NC1 or empty NC1 as control. 
For each embryo, 0.6mM MO+0.5ug/ul DNA was used for knockdown experiments and 
0.4mM MO+1.5ug/ul DNA for rescue experiments. MO was targeted to presumptive 
neural crest region with 5pulses of 5.2 V in 50 ms at 100ms intervals. Electroporated 
embryos were maintained in culture dishes with 1ml albumen, then fixed.  
 
NanoString nCounter 
Half dorsal neural folds of DNMT3AMO treated embryos were dissected in lysis buffer 
(Ambion RNAqueous-Micro Isolation kit). RNA lysates were hybridized to the probe set 
and incubated overnight at 65°C, washed and eluted according to nCounter Prep Station 
Manual and counted by nCounter Digital Analyzer.  
 
Chromatin Immunoprecipitation  
Dorsal neural tubes from 25 St.8 embryos were dissected and extracted (3 
experiments/condition). Cells were crosslinked and sonicated to yield 300-800bp 
fragments. Samples were evenly split for DNMT3A antibody (Abcam), control rabbit anti-
IgG (Abcam) and Input. Antibodies were preincubated with ProteinA magnetic beads 
(Invitrogen) before incubation with sonicated protein-DNA complex. Samples were 
washed, eluted and reverse crosslinked. Final DNA pulldown was purified and served as a 
template for qPCR of the Sox2 promoter region. Three replicates were loaded for each 
sample and results were quantified using DDCt method. Analysis was done using Applied 
BioSystems manual instructions.  
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Figure1 
 
 
Figure 1. DNMT3A is expressed at sites of neural crest formation and its loss of 
function blocks expression of neural crest specifier gene, FoxD3.  (A) Expression 
pattern of DNMT3A in St.5-9 chick embryo by in situ hybridization. DNMT3A is strongly 
expressed in the neural plate border (St.5-7) and dorsal neural tube (St.9). Scale bar 
=500um in whole mount, 100um in section (B) Western blot of dorsal neural tubes (5 
pooled embryos) shows that DNMT3A protein level was reduced on the electroporated 
compared with control side; α-tubulin levels were unchanged. (C) Two morpholinos 
against DNMT3A (MO1&MO2, FITC-inset) caused reduction of FoxD3 expression at St.8 
after electroporation (left; arrowhead) compared with the contralateral internal control side 
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or control morpholino electroporated embryos. Scale bar = 200um (D) Quantitation of 
numbers of DNMT3A MO and Control MO treated embryos with either strong or mild loss 
of FoxD3 expression of MO versus control side of same embryo. Asterisk indicates 
significant differences (P<0.01) by contingency table followed by chi-square test. See also 
Figure S1.  
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Figure2 
  
Figure 2. Loss of FoxD3 is rescued by exogenous DNMT3A in a neural crest cell 
autonomous manner. (A) Expression of DNMT3A protein in premigratory neural 
crest rescues the loss of FoxD3 phenotype:  Each embryo was electroporated on the left 
side with either DNMT3A MO or control MO (green in inset) in combination with either a 
DNMT3A rescue construct (NC1-DNMT3A) or empty vector (NC1 alone). The rescue 
construct contains the coding region of DNMT3A under control of a cranial neural crest 
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specific enhancer for FoxD3 plus HSV-tk basal promoter. At St.10, the loss of neural crest 
marker FoxD3 was largely rescued by NC1-DNMT3A plus DNMT3A MO. Over-
expression of DNMT3A rescue construct alone did not alter FoxD3 expression. Scale bar = 
500um (B) Quantitation of the percentage of DNMT3A knockdown (K.D.), Rescue (RES), 
and Overexpression (Over) embryos in (a) with either strong or mild loss of FoxD3 
expression. P<0.01 by contingency table followed by chi-square test. K.D. n=10, RES 
n=13, Over n=5. (C) Effect of DNMT3A loss of function is cell autonomous to the 
neural crest forming region:  DNMT3A MO or Control MO was electroporated 
throughout the neural tube on the left side, and into the neural tube with the exception of 
the dorsal neural folds (circled) on the right side. Loss of FoxD3 only occurred when the 
dorsal neural fold was electroporated with DNMT3A MO, as evident in transverse section. 
DNMT3A MO n=8/8, Control MO n=12/12, p<0.01 by contingency table followed by chi-
square test. Scale bar = 100um See also Figure S2. 
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Figure3 
 
 
Figure 3.  Sox2, Sox3 and Zic1 are potential downstream targets of DNMT3A, as 
identified using multiplex NanoString analysis and verified by in situ hybridization. 
(A) NanoString analysis reveals genes up-regulated (above diagonal lines) and down-
regulated (below diagonal lines) by DNMT3A knock-down.  Injected side of DNMT3A 
MO treated embryos shows >25% upregulation of neural tube genes Sox2, Sox3 and Zic1, 
n=3; there was >25% reduction of neural crest specifier genes Snail2, Sox9, TNIP1, 
FoxD3, Sox8, Sox10 (see also Figure S3). No differences were noted in control morpholino 
treated embryos, n=3 (Figure S3). Blue line represents 25% variation between injected and 
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uninjected sides. (B) Transverse sections of St.8 embryos electroporated with DNMT3A 
MO (FITZ-inset) confirms that Sox2, Sox3 and Zic1 expression was expanded into the 
neural crest territory (blue circle) when compared to internal control side, n=12/12. Scale 
bar = 200um in whole mount, 100um in section. (C) Transverse section of St.8 embryos 
electroporated with DNMT3A MO (green) confirms that Sox2 (red) protein expression was 
expanded into the neural crest territory (red circle) when compared to the internal control 
side while FoxD3 (blue) protein expression was missing in the neural crest territory (blue 
circle). n=7/8. Control morpholino treated embryos show equivalent Sox2 and FoxD3 
expression on both sides (Figure S3). Scale bar = 100um 
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Figure4  
 
 
 
Figure 4. Neural crest specifier and dorsal neural tube genes are down-regulated after 
knock-down of DNMT3A. DNMT3A MO or Control MO was electroporated into the left 
side of embryo (FITC-inset, green) and the subsequent effects on expression patterns of 
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neural crest and dorsal neural tube genes were examined by whole mount in situ 
hybridization. Sox9, Sox10, Ets1, Snail2, N-myc and Wnt1 are down-regulated 
(arrowhead) upon introduction of DNMT3A MO when compared to the internal control 
side or control morpholino electroporated embryos. Scale bar = 200um 
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Figure5 
 
 
 
Figure 5. Sox2 and Sox3 are direct targets of DNMT3A. Chromatin 
immunoprecipitation (ChIP) was used to detect binding of DNMT3A in the vicinity of 
transcriptional start site (TSS) of Sox2 and Sox3. The y axis represents input percentage 
(ChIP enriched/input) and x axis the distance from the TSS in kilobases (kb). (A) The 
results show high occupancy of DNMT3A at 0.5kb from the TSS of Sox2 at St.8. 
DNMT3A significantly binds to Sox2 at 0.5kb (0.0044% input) compared to negative 
control region ncN2 (0.0008% input) or IgG binding at 0.5kb (0.0013%input). Graph 
shows mean value ± standard deviation (SD) of a representative experiment.  (B) The 
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results show high occupancy of DNMT3A at -0.5kb and 0.5kb from the TSS of Sox3 at 
St.8. DNMT3A significantly binds to Sox3 at -0.5kb (0.0102% input) and 0.5kb (0.0069% 
input) compared to a negative control region ncN2 (0.0023% input) or IgG binding at -
0.5kb (0.0049%input) and 0.5kb (0.0011%input). Graph shows mean value ± standard 
deviation (SD) of a representative experiment.  (C) Schematic diagram summarizing 
effects of DNMT3A knockdown.   In wildtype (control side), DNMT3A (purple) directly 
represses Sox2/3 in the dorsal neural tube, thus facilitating expression of neural crest 
specifier genes like Snail2, FoxD3 and Sox10. After DNMT3A knockdown, Sox2/3 
expression expands into the dorsal neural tube region, in turn resulting in down-regulation 
of FoxD3, Snail2, Sox10 and other neural crest specifiers, and thus conferring a neural tube 
rather than neural crest fate.   
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Figure S1 
 
 
 
Figure S1, related to Figure1. (A) DNMT3A is expressed in the domain where neural 
crest cells are formed. Expression pattern of DNMT3A in the early chick embryo by in 
situ hybridization at stages 10-11. DNMT3A is expressed in the dorsal neural tube and 
migratory neural crest cells, which are identified by HNK-1 antibody staining. Scale bar = 
500 in whole mount, 100 in section (B) The decrease in FoxD3 expression corresponds 
with increases in the amount of DNMT3A morpholino introduced, suggesting dose-
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dependence. P<0.01 by contingency table followed by chi-square test. Graph shows 
quantification of percentage of embryos with strong or mild loss of neural crest specifier 
FoxD3 expression when comparing MO side versus control side of same embryo. 3A = 
DNMT3A. Con=control.  Pheno=phenotype. DNMT3A MO 0.4mM n=15, 0.5mM n=10, 
0.6mM n=17; Con0.6mM n=22. Scale bar = 200um 
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Figure S2 
 
 
 
Figure S2, related to Figure2. A mutated version of DNMT3A fails to rescue the loss-
of-function phenotype. (A) Each embryo was electroporated on the left side with either 
DNMT3A MO or control MO (green in inset) in combination with a construct containing 
either a mutated form of DNMT3A in which the catalytic domains of DNMT3A were 
removed (NC1-DNMT3A -Δcat domain) or an empty vector (NC1). The construct is under 
control of a cranial neural crest specific enhancer for FoxD3 plus HSV-tk basal promoter. 
At St.10, this mutated form of DNMT3A failed to rescue the loss-of-function phenotype. 
Over-expression of this construct alone did not alter FoxD3 expression. Scale bar = 200um 
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(B) Quantitation of the percentage of embryos in (a) with either strong or mild loss of 
FoxD3 expression. 3A MO + NC1 n=18, 3A MO + NC1-3A-Δcat n=18, con MO + NC1-
3A-Δcat n=6. (C) Both Sox2 and Sox3 are methylated in the vicinity of their 
promoters. Chromatin immunoprecipitation (ChIP) was used to detect binding of 5-methyl 
cytosine (5-MeC) in the vicinity of transcriptional start site (TSS) of Sox2 and Sox3. The y 
axis represents input percentage (ChIP enriched/input) and x axis the distance from the TSS 
in kilobases (kb). The results show high occupancy of 5-MeC at the TSS of Sox2 and Sox3 
at St.8.  5-MeC significantly binds to Sox2 at -1kb (0.0120% input) and -0.5kb (0.0067% 
input) compared to IgG binding at -1kb (0.0031%input) and -0.5kb (0.0026%input). 5-
MeC significantly binds to Sox3 at -1.5kb (0.0050% input) and -0.5kb (0.0040% input) 
compared to IgG binding at -1.5kb (0.0001%input) and -0.5kb (0.0003%input). Graph 
shows mean value ± standard deviation (SD) of a representative experiment.  (D) The loss 
of neural crest specifier gene expression is cell autonomous. FoxD3 is absent from cells 
containing DNMT3A MO but present in cells lacking DNMT3A MO (pointed by arrow) in 
the dorsal neural fold region. Scale bar = 50um 
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Figure S3 
 
 
 
Figure S3, related to Figure3. (A-B) Identifying putative downstream targets of 
DNMT3A using Nanostring. The injected side of DNMT3A MO treated embryos shows 
>25% up-regulation of neural tube genes Sox2, Zic1, EMT related genes RhoA, Cx43A1, 
placode related genes Cyp26A1, Six4, as well as ERNI and FGF2 (n=3); in addition, there 
was >25% reduction of neural crest specifier genes Snail2, Sox9, TNIP1, FoxD3, Sox8, 
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Sox10,  dorsal neural tube genes Wnt1, Wnt6 and placode genes DLX3 and Pax2; in 
contrast, no significant differences were noted in gene expression between control 
morpholino and uninjected side of the same embryo (n=3). (C) Genes up and down 
regulated for >25% upon introduction of DNMT3A MO. (D) Control morpholino treated 
embryos have equivalent Sox2 expression on both sides of the embryo. n=9/9. Scale bar = 
100um (E) Control morpholino treated embryos have equivalent Sox2 and FoxD3 protein 
expression on both sides of the embryo. n=10/10. Scale bar = 100um 
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Figure S4 
 
 
 
Figure S4, related to Figure 4. Activated β-catenin fails to rescue the loss of FoxD3 
phenotype. (A) Each embryo was electroporated on the left side with either DNMT3A MO 
or control MO (green in inset) in combination with either an activated β-catenin driven by 
pCIG (pCIG-act-β-catenin) or an empty vector (pCIG). We tested whether activated β-
catenin could rescue the DNMT3A morpholino phenotype.  However, the results show no 
change in FoxD3 expression. (B) Quantitation of the percentage of embryos in (a) with 
either strong or mild loss of FoxD3 expression. 3A MO + pCIG n=15, 3A MO + pCIG-β-
catenin n=12, con MO + pCIG-β-catenin n=8. Scale bar = 100um(C) Knock-down of 
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DNMT3A does not increase cell death. DNMT3A MO was electroporated into the left 
side and Control MO into the right side of the same embryo.  Embryos were fixed and 
sectioned at stage 9 and stained for Casp-3 immunoreactivity.  Casp-3 positive cells were 
counted and compared between the left and right side. No difference was found between 
the two sides in n=3/3 embryos.  Figure shows one representative section. Scale bar = 
100um (D) DNMT3A loss of function does not effect neural plate border genes Msx1 
and BMP4, shown in whole mount and transverse section. DNMT3A MO was 
electroporated to left side of each embryo (FITC-inset). n=6/6. Scale bar = 100um 
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Figure S5 
 
 
 
Figure S5. Over-expression of Sox2 causes down-regulation of the neural crest 
specifiers genes FoxD3, Sox10 and Snail2. Overexpression construct containing avian 
Sox2 (green in inset) or GFP (Wakamatsu et al., 2004) was electroporated into the left side 
of stage 4-5 embryos. Consistent with our findings after DNMT3A knock-down, over-
expression of Sox2 caused down-regulation of the neural crest specifier genes FoxD3, 
Sox10, and Snail2(arrowhead). Scale bar = 100um  
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Table1 
 
qPCR Primers: 
sox2 -1kb Forward GATGTCGGGAGAAGCCATAG 
sox2 -1kb Reverse GGGTTGGAAGGAAGGAGAGA 
  
sox2-0.5kb Forward ACTCCCCAAAACCACACTTG 
sox2-0.5kb Reverse GTGTTTGCAAAAGGGGGTAA 
  
sox20.5kb Forward TTGCTGATCTCCGAGTTGTG 
sox20.5kb Reverse GATGGAAACCGAGCTGAAAC 
  
Sox2 ncN2 Forward GGGGAAAGCTCTGTTTAGCC 
Sox2 ncN2 Reverse TTTTCGTCTTCGGCATTTTT 
 
Sox3-1.5kb Forward AGGAGAAAGAGCGCAGACAG 
Sox3-1.5kb Reverse GTTCCCTCCGTGTGAAAGAA 
  
Sox3-0.5kb Forward CTCTCCAAACCGACCCATTA 
Sox3-0.5kb Reverse AGGAGGGGGAAGGAGTTTTC 
  
Sox3+0.5kb Forward CACAACTCGGAGATCAGCAA 
Sox3+0.5kb Reverse CAGCAAGGTCTTGGTCTTCC 
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Chapter 3 
 
Loss of DNA methyltransferase3B prolongs neural crest EMT and causes 
premature neuronal differentiation 
 
Na Hu, Pablo Strobl-Mazzulla and Marianne Bronner 
 
To be submitted  
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Abstract 
 
The neural crest is a multipotent stem cell-like population that undergoes an 
epithelial to mesenchymal transition (EMT) to leave the central nervous system (CNS), 
migrate extensively and form numerous derivatives including peripheral ganglia and the 
craniofacial skeleton. In chick, neural crest EMT occurs over a defined period of 
approximately one day.  Little is known about the mechanisms that limit the ability of the 
CNS to produce neural crest. Here, we show that DNA methyltransferase (DNMT) 3B 
influences the ability of neural tube cells to produce emigrating neural crest cells. DNA 
methyltransferase 3B is expressed in the dorsal portion of the developing neural tube from 
early stages. Interestingly, morpholino-mediated knock-down in chick causes an excess of 
neural crest emigration, by extending the time that the neural tube is competent to generate 
migratory neural crest cells. Concomitant with up-regulation of neural crest genes, like 
Snail2, Sox10 and FoxD3, there is a loss of neural tube markers such as Wnt3A. In older 
embryos, this resulted in precocious neuronal differentiation. These results support an 
important role for DNA methylation in regulating the duration of neural crest production by 
the neural tube and the timing of their differentiation.  
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Introduction 
 
The neural crest is a multipotent population, unique to vertebrates, that contributes 
to a wide variety of derivatives including sensory and autonomic ganglia of the peripheral 
nervous system, cartilage and bone of the face, and pigmentation of the skin. Neural crest 
progenitors arise at the neural plate border, between neural and non-neural ectoderm, and 
after neurulation, reside within the dorsal aspect of the central nervous system. They then 
undergo an epithelial to mesenchymal transition (EMT) and delaminate from the neural 
tube as migratory, mesenchymal cells that navigate to diverse and sometimes distant 
locations.  The timing of both onset and cessation of neural crest emigration from the 
neural tube is stereotypic. For example, in birds, neural crest cells initiate emigration 
shortly after neural tube closure and cease emigration about one day later. The proper 
timing and degree of neural crest production and appropriate migration is critical for 
normal development of the peripheral nervous system and craniofacial skeleton. Indeed, 
dysregulation of these events can result in neural crest related birth defects and peripheral 
neuropathies.  
 
The initiation of neural crest emigration from the neural tube has been the subject of 
many studies. At trunk levels, for example, it has been reported that neural crest 
delamination depends upon appropriate levels of BMP signaling which in turn regulate the 
G1/S cell cycle transition of emigrating neural crest cells in a Wnt-dependent manner 
(Burstyn-Cohen et al. 2004). In addition, transcription factors like Snail2 play an important 
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role in EMTs of cancer cells as well as neural crest cells (Cano et al. 2000; del Barrio and 
Nieto 2002; Strobl-Mazzulla and Bronner 2012b). In contrast, the mechanisms that limit 
the ability of the neural tube to produce neural crest cells over time are poorly understood. 
Single cell lineage analyses of the newly closed neural tube have shown that individual 
precursor cells can give rise to both neural crest and neural tube derivatives (Bronner-
Fraser and Fraser 1988; McKinney et al. 2013). This raises the intriguing possibility that 
unknown factors, such as epigenetic modifiers, may progressively limit the ability of 
presumptive central nervous system cells to produce neural crest cells, by influencing the 
balance between neural tube versus neural crest cell fate. Consistent with this possibility, 
we recently found that a DNA methyltransferase (DNMT3A) plays an early function in 
repressing the neural genes Sox2 and Sox3 in the presumptive neural crest region, and this 
is a prerequisite for neural crest specification (Hu et al. 2012).   
 
DNA methyltransferases function in de novo methylation, catalyzing transfer of a 
methyl group to the cytosine residues on DNA (Cheng and Blumenthal 2008). Generally, 
most mammalian genomes are highly methylated at CpG islands within promoter regions, 
where DNA methylation has a repressive effect. A similar situation has been observed for 
cancer and stem cells (Momparler and Bovenzi 2000; Miranda and Jones 2007; Altun et al. 
2010). Both DNMT3B and its paralog, DNMT3A, are essential for de novo methylation 
and have been shown to play important roles in disease as well as mammalian development 
(Linhart et al. 2007; Ehrlich et al. 2008). Whereas mouse knock-outs of DNMT3A were 
nonviable, DNMT3b -/- embryos have rostral neural tube defects and growth impairment 
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(Okano et al. 1999). Moreover, mutations in human DNMT3B are found in ICF 
(immunodeficiency-centromeric instability-facial anomalies) syndrome, comprised of 
facial abnormalities, neurological dysfunction and other related defects (Jin et al. 2008).  
Similarly, in zebrafish, loss of DNMT3 causes defects in craniofacial structures and 
abnormal neurogenesis (Rai et al. 2010). In human embryonic stem cells, knockdown of 
DNMT3B accelerates neural and neural crest differentiation and increases the expression of 
neural crest specifier genes (Pax3, Pax7, FoxD3, Sox10 and Snail2). DNMT3B expression 
is significantly upregulated during neural crest induction in chicken embryos (Adams et al. 
2008). All of these data are consistent with an important role for DNMT3B in neural crest 
development. In contrast to the human syndrome and stem cells data, however, conditional 
knock-down of DNMT3B in the mouse neural crest using Wnt1- or Sox10-cre does not 
produce an apparent craniofacial phenotype (Jacques-Fricke et al. 2012). Both DNMT3B 
null and Wnt-1 cre driven DNMT3B knockout mice exhibit only mild migration defects, 
reflected by dispersed Sox10 positive cells that recover during cranial gangliogenesis. This 
could reflect differences between species, or may indicate that the primary function of 
DNMT3b is in non-neural crest tissue.  
 
To resolve the possible species specific roles of DNMT3B in the neural crest, we 
turned to the chick embryo, which affords several advantages.  Bird embryos are easily 
accessible to experimental perturbation at early stages of development, while developing in 
a manner that is morphologically nearly identical to that of human embryos at comparable 
stages.  This allows for temporally and spatially controlled manipulation of gene 
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expression.  Moreover, it is possible to perform perturbations that affect only one side of 
the embryo, with the opposite side serving as an internal control. Using this paradigm, our 
results show that knock-down of DNMT3B in the cranial neural crest during stages of 
neural crest EMT prolongs the production of neural crest cells by the neural tube, and up-
regulates expression of key neural crest transcription factors like Sox10, Snail2 and FoxD3. 
Our findings suggest an important role for DNMT3B in regulating the length of time 
during which the neural tube is able to produce migratory neural crest cells, thus affecting 
the numbers of migrating neural crest cells and the timing of their differentiation. 
 
Results 
 
In a screen for genes up regulated during neural crest development, we identified 
several epigenetic factors, including the DNA methyltransferase 3B (DNMT3B) (Gammill 
and Bronner-Fraser 2002; Adams et al. 2008). 
 
DNMT3B is expressed in regions of neural crest formation and migration  
 
As a first step in establishing its functional significance, we examined the 
expression patterns of DNMT3B transcripts during early stages of chick embryonic 
development ranging from gastrulation to the formation of neural crest derivatives, 
focusing on the cranial neural crest. The results show that DNMT3B is expressed in the 
dorsal neural tube and migratory crest cells (Fig.1). It is initially expressed throughout the 
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neural tube at stage 8 but becomes restricted to the dorsal neural tube by stage 10. Using 
HNK-1 staining as a marker for migrating neural crest cells, we found co-localization of 
DNMT3B with HNK-1positive migrating neural crest cells as well as neural crest 
derivatives. In addition, DNMT3B also was expressed in the gastrula-stage embryo, with 
broad expression throughout the neural plate and at the neural plate border where neural 
crest cells are induced (Fig.1). Since the expression of DNMT3B becomes exclusively 
expressed in the neural crest territory during the migratory stages, we hypothesize that it 
plays a crucial role in neural crest migration. 
 
Loss of function of DNMT3B causes prolonged production of neural crest cells from 
the neural tube, but does not affect neural crest induction 
 
To examine whether DNMT3B played a role in neural crest specification similar to 
its paralog DNMT3A (Hu et al. 2012), we tested the effects of its loss-of-function on neural 
crest gene expression. We used fluorescein-tagged antisense morpholino oligonucleotides 
(MO) to the region overlapping ATG codon to block translation of DNMT3B protein at 
early stages. MOs plus carrier DNA were injected into one half of embryos at stage 4, with 
the uninjected side serving as an internal control. Despite the fact that DNMT3B is 
expressed as early as stage 4, no changes in expression of neural crest markers Sox10 or 
FoxD3 were noted at stages of neural crest induction (data not shown).  
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To test whether DNMT3B played a later role in neural crest development, the 
above experiments were repeated in ovo as the neural folds were elevating during stage 8 
(Fig. 2B). Subsequent effects on neural crest production were examined at stage 12, by 
which time cranial neural crest emigration has ended in control embryos. The effects of 
DNMT3B knock-down were evaluated by analyzing neural crest and neural tube genes 
expression.  Interestingly, the results suggested that morpholino-mediated knock-down of 
DNMT3B caused excess and/or prolonged emigration of the neural crest cells. The neural 
crest specifier genes Sox10 and Snail2 come on shortly before initiation of migration and 
later are maintained on migrating neural crest cells. In situ hybridization for Sox 10 and 
Snail2 reveals differences in the patterns of neural crest emigration and/or gene expression 
between the control and experimental side. Whereas Sox10 or Snail2 positive neural crest 
cells were observed some distance away from the neural tube on the control side, they 
appeared to be continuing to emigrate from the morpholino-treated side (Fig. 2A, C, D).  
Furthermore, we noted no alterations in the time of onset of neural crest emigration (Sup 
Fig.1).   
 
To demonstrate morpholino specificity, control morpholino was injected in a 
similar fashion as function-blocking morpholino. These control embryos displayed 
equivalent migratory patterns on both sides, consistent with the fact that emigration of 
cranial neural crest cells had ceased by stage 12 (Fig. 2A, C, D). To further demonstrate 
specificity, co-electroporation of a second DNMT3B morpholino different in sequence than 
the first morpholino produced an identical phenotype (Fig. 2A).   
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 To definitively test the effects of DNMT3B knock-down on the time course of 
neural crest emigration, we labeled neural tubes with the lipophilic dye, DiI, at time points 
after neural crest cell emigration had concluded in the head (stage 12).  Normally, cranial 
neural crest cells emigrate from the neural tube for 8 to 16 hours, depending upon the exact 
axial level, with the last cells emigrating at midbrain levels by the 14-15 somite stage (stage 
11).  Accordingly, when embryos treated with control morpholinos were labeled with DiI at 
stage 12, DiI label remained within the cranial neural tube (Fig.2E n = 7/7), with no DiI 
labeled neural crest cells observed migrating at the level of the midbrain or rostral 
hindbrain. In contrast, in DNMT3B-MO treated embryos, DiI-labeled migrating neural 
crest cells continued to emigrate from the neural tube at the midbrain and rostral hindbrain 
levels on the morpholino-injected side (Figure 2E; n = 4/9 embryos). A few DiI-labeled 
cells also were noted on the contralateral side. These likely represent ones generated from 
the morpholino-treated side that crossed the midline, given that approximately 20% of 
neural crest cells “cross” to the opposite side (McKinney et al. 2013).  These results 
definitively show that DNMT3B morpholino-treated neural tubes continue to produce 
cranial neural crest cells on the injected side well beyond the time neural crest emigration 
normally had ceased in control embryos. 
 
Multiplex analysis reveals that loss of DNMT3B up-regulates neural crest specifier 
genes, while down-regulating dorsal neural tube genes 
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In order to understand global changes in gene expression caused by DNMT3B 
knock-down, we performed Nanostring analysis to monitor and quantify 73 transcripts 
including genes expressed in the neural crest, neural tube, neural plate, neural plate border 
placodes, nonneural ectoderm, and those involved in cell proliferation and cell death. Each 
DNMT3B knockdown embryo was analyzed at stage 12, by comparing the morpholino 
electroporated side to the uninjected side of the same embryo. Because DNMTs are thought 
to inhibit transcription by methylating the promoter region of target genes, we were 
particularly interested in genes that were up-regulated as a consequence of down-regulating 
DNMT3B, as these represent potential direct targets. Interestingly, the results show that 
neural crest specifier genes Sox9, Sox10, Snail2, and FoxD3 were all up-regulated as a 
result of DNMT3B knock-down (Fig. 3A).  In contrast, the dorsal neural tube gene Wnt3A 
and Type I cadherin Ncad were both down-regulated. Cell proliferation was unchanged as 
indicated by the PCNA marker. This further supports the possibility that the prolonged 
emigration of neural crest cells after DNMT3B knock-down occurs at the expense of dorsal 
neural tube cells. To verify changes in Wnt3A expression, we performed in situ 
hybridization and indeed observed loss of Wnt3A mRNA expression on the DNMT3B 
morpholino-treated side of the neural tube (Fig. 3B). In contrast, expression of neural tube 
genes Sox2 and Sox3 were not affected at stage 12.  
 
Loss of DNMT3B results in extra migratory neural crest cells 
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 To examine if the prolonged emigration of neural crest cells upon loss of 
DNMT3B results in more migratory neural crest cells, we collected embryos at later stages 
and examined the expression of HNK1 epitope, a marker for migratory neural crest cells. 
When compared to the control side of each embryo, the DNMT3B knockdown side had 
many more neural crest cells as shown in both whole mount embryos and in transverse 
sections (Fig. 4A, 4B).  There was no apparent increase in cell death between the control 
and experimental side of the embryos, as assayed by Caspase 3 staining as a marker (data 
not shown). Similar to stage 12, excess neural crest cells were noted on the DNMT3B 
knockdown side at stage 13 (Fig.4C). 
  
Loss of DNMT3B results in premature differentiation of the trigeminal ganglia  
 
To examine later effects of DNMT3B knock-down, embryos were stained with 
Tuj1 as a marker of neuronal differentiation in the trigeminal ganglia. Surprisingly, we 
observed premature differentiation of trigeminal neurons and early condensation of the 
ganglion on the DNMT3B morpholino-treated side of the embryo (Fig. 5). Whereas 
neuronal differentiation was just beginning on the uninjected side or in control morpholino 
treated stage 13 embryos, we observed a well-differentiated and condensed trigeminal 
ganglia with obvious ophthalmic and maxillo-mandibular lobes on the DNMT3B 
morpholino treated side.  
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Discussion 
 
De novo DNA methylation may be one of the main epigenetic marks used for cell 
fate restriction of progenitor cells during cell fate differentiation. The paralogues DNMT3A 
and DNMT3B both have been implicated in de novo DNA methylation and have some 
overlapping functions. However, they also seem to play distinctive roles during 
development. This is evidenced by the observation that DNMT3A-null mice die several 
weeks after birth, whereas DNMT3B-null mice are nonviable and embryos exhibit severe 
defects including rostral neural tube defects and growth impairment (Okano et al. 1999). 
Moreover, our recent work in chick embryos shows that DNMT3A plays an important role 
during neural crest specification by acting as a molecular switch mediating the neural tube-
to-neural crest fate transition (Hu et al. 2012), whereas DNMT3B lacks a function at this 
stage of development. DNMT3A promotes neural crest specification by repressing, via 
promoter DNA methylation, neural genes like Sox2 and Sox3 in the neural crest territory. 
These data provide insights into the mechanisms that determine whether a cell becomes 
part of the central nervous system or peripheral nervous system. On the other hand, 
mutations in human DNMT3B result in ICF (immunodeficiency-centromeric instability-
facial anomalies) syndrome, in which patients exhibit facial abnormalities (Jin et al. 2008), 
suggesting a defect related to abnormal neural crest development.  
 
The present results demonstrate the necessity of de novo DNA methylation, exerted 
by DNMT3B, for proper timing of the cessation of neural crest emigration from the dorsal 
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neural tube at cranial levels. A recent report in mice using neural crest-specific conditional 
deletion of DNMT3B failed to detect obvious defects in neural crest migration or 
differentiation and morphogenesis into craniofacial and cardiac structures (Jacques-Fricke 
et al. 2012). One possibility for the difference between these findings in different species is 
that the neural crest defect obtained in DNMT3B mutant mice may be due to a requirement 
for this protein in neighboring cell types. Alternatively, this may reflect a species 
difference. Chick lacks DNMT3L, which is present in mouse. Since DNMT3A and 3B are 
paralogues, it may not be surprising that each paralogue assumed slightly different roles in 
different species. In chick, we find that DNMT3A and 3B are not redundant to one another 
during neural crest development, but they may be different and somewhat overlapping in 
the mouse. Although DNMT3B null mice have mostly normal neural crest development, 
Jacques-Fricke and colleauges do describe ectopic migrating neural crest cells dispersed 
dorsal to the normal neural crest streams (Jacques-Fricke et al. 2012). This is similar to the 
prolonged emigration of neural crest cells we observed in our DNMT3B MO treated chick 
embryos, which results in abnormally migrating neural crest cells. However, this may be a 
less obvious phenotype in the null mice, since it is not possible to compare control and 
experimental sides in the same embryo in mice as it is in chick.  Finally, DNMT3B may be 
required in mouse neural crest development prior to the onset of Wnt1-driven cre 
expression, resulting in a less obvious phenotype. 
 
In addition to de novo DNA methytransferases, other epigenetic regulators such as 
histone demethylases and histone deacetylases have also been shown to play a crucial role 
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regulating the timing of neural crest specification or migration. Histone demethylases such 
as members of the Jumonji family revert histone methylation (Tan et al. 2008). In neural 
crest development, histone demethylase of the Jumonji family JmjD2A (also known as 
KDM4A) is discovered to regulate neural crest specification (Strobl-Mazzulla et al. 2010). 
JmjD2A is expressed in the neural crest territory during neural crest specification and 
knocking down JmjD2A causes dramatic loss of neural crest specifier genes such as Sox10, 
Snail2, FoxD3, etc. In vivo ChIP assays reveal direct interaction of JmjD2A with Sox10 
and Snail2 promoter regions (Strobl-Mazzulla et al. 2010). JmjD2A is required to 
demethylate Sox10 and Snail2 at the proper time and place to allow neural crest 
specification to take place.  
 
Moreover, histone deacetylace (HDAC) repression complex plays an essential role 
in regulating neural crest migration. Premigratory neural crest cells from the dorsal neural 
tube undergo an epithelial to mesenchymal transition to gain migratory property and travel 
to distant parts of the body. The transcriptional repressor Snail2 has been reported to 
directly repress the adhesion molecule Cadherin6B in premigratory neural crest cells (Hatta 
et al. 1987; Nakagawa and Takeichi 1995; Taneyhill et al. 2007). Epigenetic regulation has 
been shown to play a critical underlying molecular role in this repression (Strobl-Mazzulla 
and Bronner 2012b). In particular, an interaction between PHD12, a member of the histone 
deacetylase complex, and Snail2 makes it possible to recruit the repressive complex 
Sin3A/HDAC to Cad6B promoter region and as a result turn off Cad6B transcription via 
histone deacetylation to allow neural crest cells to gain migratory property (Strobl-
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Mazzulla and Bronner 2012b). Overall, epigenetic regulators influence neural crest 
formation throughout different temporal time points.  
 
One of the main questions in vertebrate development is to understand what 
regulates the spatial and temporal progression of the genetic program underlying neural 
crest development in such an exquisite manner. Our results in avian embryos suggest that 
de novo DNA methylation, exerted by both DNMT3A and DNMT3B, plays a dual role in 
neural crest development. First, DNMT3A appears to limit the spatial boundary between 
neural crest versus neural tube progenitors, repressing the expression of neural marker in 
the neural crest forming territory. Second, DNMT3B appears to restrict the temporal 
window during which the neural crest cells emigrate from the dorsal neural tube.  Thus, 
interfering with DNMT3A or 3B results in craniofacial problems, but each appears to 
primarily function during a different temporal window of neural crest development. 
 
 
Materials and methods 
 
Embryos 
Fertilized chicken eggs were incubated at 37°C to desired stages.  
 
In situ hybridization 
Dioxigenin-labled RNA probes were made from cDNA plasmids or ESTs of DNMT3B, 
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Sox10, Snail2, Wnt3A, Sox2, and Sox3. Embryos were fixed with 4% paraformaldehyde, 
washed with PBS/0.1% Tween, dehydrated in MeOH, and stored at -20C. Whole mount 
chick in situ hybridization was performed according to the methods in (Acloque et al. 
2008); Wilkinson 1992). Embryos were imaged and subsequently sectioned at 14-16 µm. 
 
Immunohistochemistry 
Anti-TuJ1 (Covance) was used and diluted 1:250 and anti-HNK1 was diluted 1:10. 
Secondary antibodies against the primary antibody subtype were conjugated to Alexa Fluor 
488, 568, or 350 dyes (Molecular Probes).  Images were taken on a Zeiss Axioskop2 plus 
fluorescence microscope. 
 
In ovo electroporation 
Embryos were electroporated at stage 8 as described in (Sauka-Spengler and Barembaum 
2008) using DNMT3B MO1 (over ATG codon): 
CGAGGCTCGTTACCATGCTCATCGC and DNMT3B MO2 (upstream of ATG): 
GAACGGAGTGATGACAATGATACCT. DNMT3B MOs or Control MOs were 
introduced into the open neural tube at stage 8.  A charge was applied to transfect the 
morpholino into the right side of the neural tube. The embryos were then sealed and 
incubated at 37oC until they reach the indicated stage of analysis. 
  
NanoString nCounter 
Half dorsal neural folds of DNMT3B MO treated embryos were dissected in lysis buffer 
  
81 
(Ambion RNAqueous-Micro Isolation kit) at St.12. RNA lysates were hybridized to the 
probe set and incubated overnight at 65°C, washed and eluted according to nCounter Prep 
Station Manual and counted by nCounter Digital Analyzer.  
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Figures and Figure Legends 
 
Figure1 
 
 
Fig. 1 DNMT3B is expressed in the neural crest territory at the proper time and stage. 
Expression pattern of DNMT3B in St.4-14 chick embryo by in situ hybridization. During 
St.4-8, DNMT3B is expressed throughout the neural plate (green arrowhead) and neural 
plate border (blue arrowhead). During the migratory stages (St. 10-11), expression of 
DNMT3B is restricted to the dorsal neural tube and migratory neural crest cells (black 
arrowhead). Using HNK-1 staining (red) as a marker for migrating neural crest cells, we 
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found co-localization of DNMT3B with HNK-1positive migrating neural crest cells as 
well as neural crest derivatives. DNMT3B is not expressed at St.14. Dashed line shows the 
level of cranial region being cross-sectioned.  
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Figure2 
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Fig. 2 Loss of function of DNMT3B causes prolonged migration of neural crest cells 
using Sox10, Snail2 and DiI as markers. (A) Two morpholinos against DNMT3B 
(MO1&MO2, FITC-inset) caused prolonged emigration of neural crest cells. The right side 
of each neural tube was electroporated with DNMT3B MO or control morpholino. Cranial 
neural crest cells marked by Sox 10 or Snail2 appear to keep emigrating from the neural 
tube for longer time periods (arrow) on the side electroporated with DNMT3B MO when 
compared to their internal control side. Embryos electroporated with control morpholino 
appear normal. Asterisk marks the side of morpholino injection. (B) Schematic graph 
summarizing in ovo electroporation. Morpholino was introduced at St.8 and electroporated 
onto the right side of the neural tube in each embryo. Embryos were incubated until St.12, 
at which time neural crest cells at this axial level have normally ceased emigration. (C) 
Quantitation of percentage of DNMT3B MO or Control MO treated embryos with either 
strong or mild prolonged emigration phenotype using Sox10 or Snail2 as markers. 
Expression was compared between MO treated side and control side of the same embryo. 
Sox10, n=21 with DNMT3B MO, n=9 with Control MO; Snail2, n=18 with 3B MO, n=11 
with Control MO. Asterisk on graph means P < 0.05 using Chi-square contingency test. (D) 
Transverse sections of embryos treated with DNMT3B MO versus Control MO. Sox10 
positive neural crest cells continue to emigrate out of the neural tube (arrows) on DNMT3B 
MO treated side compared with the internal control side. In Control MO treated embryos, 
emigration has ceased on both sides. FITC-inset shows morpholino incorporation. 
Asterisks mark side of MO injection. (E) Embryos were electroporated with MO at St.8 
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into the right side of the neural tube (asterisk) and DiI was used to label the entire neural 
tube during early St.12, by which time emigration has ceased in normal embryos. Embryos 
were collected and sectioned at St.13. Prolonged emigration was observed (arrows) on the 
side treated with DNMT3B MO while no emigration was observed on the uninjected side 
or Control MO treated side. 4/9 embryos treated with DNMT3B MO and 0/7 embryos 
treated with Control MO have prolonged emigration phenotype.  
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Figure3 
 
 
  
88 
Fig. 3 Neural crest specifier genes such as Snail2, Sox10 and FoxD3 are up-regulated 
upon loss of DNMT3B as identified using multiplex Nanostring analysis and 
concomitantly, dorsal neural tube gene Wnt3A is down-regulated. (A) Nanostring 
analysis revels genes up-regulated (above diagonal lines) and down-regulated (below 
diagonal lines) by DNMT3B knock-down. Injected side of DNMT3B MO treated embryos 
shows >25% up-regulation of neural crest specifier genes Sox10, Sox9, Snail2 and FoxD3; 
there was >25% down-regulation of dorsal neural tube gene Wnt3A and Type I cadherin 
Ncad. (n=5) (B) In situ data further verifies that loss of DNMT3B causes reduction of 
dorsal neural tube gene Wnt3A when compared to the internal control side and to control 
embryos, at the time window in which prolonged emigration of the neural crest cells were 
observed in DNMT3B MO treated embryos. 10/12 embryos treated with DNMT3B MO 
and 1/6 embryos treated with Control MO show reduction of Wnt3A. 
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Figure4 
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Fig. 4 DNMT3B knock-down results in extra migratory neural crest cells. (A) 
Embryos electrporated with DNMT3B MO or Control MO were immunostained with anti-
HNK1 antibody and sectioned. DNMT3B MO injected side of the embryo (asterisk) show 
increased number of HNK1 positive neural crest cells in both whole mount and transverse 
section view. (B) Quantitation of percentage of DNMT3B MO (3B) or Control MO (Con) 
(in mM concentration) treated embryos with either strong or mild phenotype of generating 
extra migrating neural crest cells on the electroporated side versus internal control side. 
n=13 for 3B  1.5mM, n=8 for Con 1.5mM, n=9 for 3B 2.5mM, n=8 for Con 2.5mM. 
Asterisk on graph means P < 0.05 using Chi-square contingency test. (C) Embryos 
collected at St.13 continue to exhibit extra neural crest cells (arrow, n=5/7) using Sox10 as 
a marker on the DNMT3B MO treated side (asterisk) versus the control side in both whole 
mount and section view.  
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Figure5 
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Fig. 5 DNMT3B knock-down results in premature differentiation of the trigeminal 
ganglia. 
The right half (asterisk) of each embryo was electroporated with DNMT3B MO, DNMT3B 
MO2 or Control MO (FITC) and Tuj1 was used as a marker for neuronal differentiation in 
the forming trigeminal ganglia. Premature differentiation of the trigeminal ganglia (well-
condensed ganglia with both ophthalmic, maxillo-mandibular lobes) was observed in 
DNMT3B MO treated side of the embryo when compared to control side that shows 
normal ganglion aggregation. 4/6 embryos treated with DNMT3B MO and 0/6 embryos 
treated with Control MO show premature differentiation of the trigeminal ganglia. 
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Figure S1 
 
 
Fig. S1 Knockdown of DNMT3B does not affect early migrating neural crest cells. 
Right side (asterisk) of each neural tube was electroporated with DNMT3B MO or control 
morpholino during St.8 and embryos were scored at early St.10, the onset of neural crest 
migration. Cranial neural crest cells marked by Sox10 seem to be normal between control 
and injected side of each embryo.  
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Chapter 4 
 
Conclusions and future perspectives 
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Summary and Significance 
 
In this thesis, I have dissected the roles of DNMT3A and DNMT3B in neural crest 
development in developing embryos. During neural crest specification, DNMT3A is 
expressed in the region where neural crest cells originate. Its loss of function leads to 
ectopic upregulation/expansion of neural genes Sox2 and Sox3 in the dorsal neural tube 
(neural crest forming region) at the expense of neural crest makers such as Snail2, Sox10 
and FoxD3, in a cell autonomous manner. Using Nanostring multiplex analysis, we show 
concomitant upregulation of neural genes and down-regulation of neural crest genes in the 
same embryo after treatment with DNMT3A morpholino. We then confirmed that ectopic 
expression of neural genes such as Sox2 in the neural crest region is sufficient to inhibit 
neural crest markers Sox10, Snail2 and FoxD3. In vivo ChIP further demonstrates that 
DNMT3A specifically associates with CpG islands in the Sox2 and Sox3 promoter region, 
resulting in methylation leading to their repression. Therefore, during neural crest 
specification, DNMT3A first directly represses neural genes Sox2 and Sox3 in the dorsal 
neural tube, facilitating expression of neural crest markers Snail2, Sox10 and FoxD3. These 
data show that DNMT3A functions as a molecular switch mediating neural tube to neural 
crest fate transition.  
 
During neural crest EMT, DNMT3B expression is restricted to the dorsal neural 
tube and migratory neural crest region. Its loss of function extends the time window of 
neural crest emigration, which results in an excess of migratory neural crest cells using 
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Sox10, Snail2, and FoxD3 as markers. In the meantime, there is a loss of the dorsal neural 
tube gene, Wnt3A, indicating that the excess neural crest cells formed at the expense of 
neural tube cells. In later stages, this is manifested in the premature neural differentiation of 
the trigeminal ganglia. The effect is particularly severe in the maxillo-mandibular lobe of 
the trigeminal ganglia, the lobe that is heavily contributed by cells of neural crest origin. 
The data suggest that DNMT3B plays an important role in regulating the duration of neural 
crest emigration and the timing of their differentiation into craniofacial ganglia.  
 
This thesis project identified key molecular players necessary for neural crest cell 
fate specification and neural crest EMT. My results show that epigenetic regulation at the 
level of DNA modifications is a novel mechanism for regulation of neural crest 
development. Second, the data show that de novo DNMTs have a specific role at specific 
times in making key developmental decision for the embryo. Rather than acting 
ubiquitously, these enzymes appear to be exquisitely controlled in space and time. Third, I 
demonstrate that negative input is essential for promoting neural crest cell fate. In this case, 
Sox2/Sox3 must be turned off by DNMT3A in order to achieve a positive outcome of 
specifying neural crest cells. Fourth, my results provide the first molecular evidence that 
DNMT3B is involved in the termination of neural crest EMT. This promises to open future 
studies regarding factors that stop the generation of migrating neural crest cells from the 
dorsal neural tube. Finally, our work provides important insights into explaining the long-
standing mystery of what makes a precursor cell part of the central nervous system versus 
peripheral nervous system. 
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In the future, these findings have implications for stem-cell therapy, by giving clues 
as to how to engineer stem or iPS cells to become neural crest cells. For example, ongoing 
research is attempting to define the conditions needed to induce iPS cells to neural crest 
derivatives. Our results showing that DNMT3A is important for converting CNS cells to 
neural crest cells will be useful in defining the steps needed to reprogram such iPS cells and 
then use them to repair human diseases.  
 
Future Perspectives 
 
 From this study, I now propose some possible future directions that stem from this 
thesis to further dissect the molecular mechanisms of de novo DNA methylation in neural 
crest and neural crest related development.  
 
Exploring epigenetic regulation in placode development 
 
Given these results, we speculate that DNMTs may have important functions in the 
embryo at different places and times. One possible future direction is to examine the roles 
of these enzymes in placode development. Placodes are discrete, thickened regions of the 
head ectoderm that invaginate from the surface ectoderm and migrate into the adjacent 
mesenchyme. They form in pairs on both sides of the neural tube and contribute to the 
formation of the olfactory epithelium, trigeminal ganglia, lens of the eye, and structures in 
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the ear. Placode and neural crest precursors both originated from the neural plate border 
during gastrula stage. Later, neural crest cells occupy the dorsal neural tube region while 
placode cells reside outside of the neural plate as patches of thickened ectoderm. My 
preliminary data indicate that DNMT3A may be involved in olfactory placode formation. 
Knocking down DNMT3A at St.5 leads to loss of olfactory tissues at St.8 (Figure1). It will 
be interesting to characterize the involvement of DNMT3A in olfactory placode 
development and compare/contrast its mechanism of regulation with neural crest 
development. To do this, we would first characterize the expression of DNMT3A in the 
olfactory placode region to determine wether it co-localizes with olfactory placode 
markers. Loss of function experiments will then be performed and data will be collected at 
different stages of olfactory formation to examine the influence of DNMT3A on olfactory 
development. By in situ hybridization and immunostaining for olfactory placode markers 
we might be able to find potential direct targets. To further confirm a possible interaction 
we would perform ChIP followed by qPCR to identify a possible direct regulatory 
relationship between DNMT3A and genes involved in olfactory placode development. 
 
Another possible direction is to investigate the roles of DNMT3A and/or 3B in 
trigeminal ganglia formation. The trigeminal ganglion is derived from a mixture of cells 
originating from both neural crest and placodes. My preliminary data shows that loss of 
DNMT3A and 3B in the neural crest cells eventually leads to premature ganglion 
formation. Depending on the stages examined, the maxillo-mandibular lobe appeared to be 
more severely affected by the loss of DNMT3A and 3B than the ophthalmic lobe (Figure 
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2). This is not surprising because the maxillo-mandibular lobe contains more of a neural 
crest contribution than the ophthalmic lobe. In the future, it will be interesting to examine 
the roles of DNMT3A and/or DNMT3B in the trigeminal placode. This could be done by 
specifically knocking down DNMT3A and/or 3B in the trigeminal placode cells and 
examining the formation of the trigeminal ganglion. This study would allow us to 
distinguish the differential contribution of DNMTs in neural crest cells versus placode 
cells, and how this ultimately affects the formation of the trigeminal ganglia.  
 
Identification of co-factors of DNMTs in neural crest development 
 
 In chapter 2, we show that loss of DNMT3A maintains Sox2 and Sox3 expression 
in the dorsal neural folds, and this in turn leads to repression of neural crest specifier genes. 
However, it still remains unclear how DNMT3A’s effect is restricted only to the dorsal 
neural fold region during neural crest specification. Identifying co-factors would inform 
about how spatial and temporal specificity is conferred by de novo DNA methylation. 
Although the mechanism by which DNMT3A is recruited to the promoter region of target 
genes is unknown, they have been shown to interact with numerous factors on transcription 
factor arrays (Hervouet et al. 2009). Although these have yet to be validated, particularly in 
vivo, this list includes some neural plate border and neural crest specifier genes like Msx1, 
tfAP2a, Id2 and Myc. Thus, it is intriguing to speculate that DNMT3A may be recruited to 
the promoter region of neural genes by some of these transcription factors that are 
selectively expressed in the neural crest forming domain. To test the possible interactions 
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of these transcription factors with DNMT3A, dorsal neural folds of embryos at stages of 
neural crest induction and specification can be collected for co-IP analysis to find evidence 
of in vivo binding. To visualize protein interactions within living cells, Bimolecular 
fluorescence complementation (BiFC) can be used to capture DNMT3A interacting with its 
co-factors. For this, full length DNMT3A coupled to the Venus N-terminus domains, and 
neural crest co-factors of interest coupled to the Venus C-terminus domains can be 
transfected into chick fibroblasts and an interaction would be visible by a green fluorescent 
Venus signal since it is only detectable when two proteins directly interact with each other.  
 
Identification of novel downstream targets of DNMTs in neural crest development 
 
The availability of high throughput technologies such as RNA-seq and ChIP-seq, it 
will be of great benefit for the identification of novel regulators in neural crest 
development. For example, ChIP-seq can be used to map the genome-wide binding of 
DNMTs during different stages of neural crest development to obtain genome scale 
information of the downstream targets regulated by DNMTs as well as which positions 
DNMTs bind in vivo. To pinpoint the methylated sites, this experiment can be further 
modified to incorporate bisulfite treatment that converts unmethylated cytosine to uracil 
while leaving methylated cytosine unchanged. By comparing sequence data from treated 
and untreated DNA, methylation sites can be identified. A good quality antibody is crucial 
to perform such types of experiments in order to get high signal and low background.  
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Alternatively, morpholino knockdown followed by RNA-seq is another possibility 
to find novel targets. For this, embryos would be treated with DNMT3A and/or 3B 
morpholino on one side, leaving the other side as internal control. Neural crest tissues from 
morpholino treated sides and control sides can be dissected, sequenced, compared for 
changes that occur in novel genes that are not included in our Nanostring probet set, which 
I described earlier. From our previous study we know that DNMT3A mediates neural 
versus neural crest cell fate choice and DNMT3B regulates neural crest EMT. Therefore, 
changes in genes involved with cell fate choice and EMT will be particularly interesting to 
us as they are very likely to be direct targets. Although this alternate experiment would not 
isolate direct binding targets, it is still informative in terms of identifying potential novel 
targets of DNMTs. These candidates will be further validated in vivo for expression at 
proper times and places and their specific functions in neural crest development will also be 
further studied in chick. From this study, we hope to uncover novel genes involved in 
neural crest development and bring new additions to our current neural crest gene 
regulatory network.  
 
Cis-regulatory analysis to identify DNMT3A and DNMT3B enhancers 
 
Since DNMTs play a crucial and specific role in neural crest development and 
their tissue specific expression changes considerably during chick developmental stages, 
it would be interesting to dissect the cis-regulatory regions of DNMTs and investigate 
how their transcription is being controlled. Putative regulatory regions can be cloned into 
  
102 
expression vectors and electroporated in chick to study their individual expression. Once 
an enhancer region(s) is narrowed down to its minimal size and still capable of driving 
expression, mutational studies can be carried out to identify specific functional binding 
sites in the region. This study will identify the direct regulatory inputs of DNMTs and 
give us a more global picture of neural crest formation.  
 
Establish direct relationships between DNMT3B and regulatory regions of EMT 
genes and neural crest specifier genes 
From Chapter 3, we concluded that DNMT3B controls the termination time of 
neural crest EMT and/or maintenance of neural crest specifier expression. One possible 
mechanism is that DNMT3B represses EMT genes and thus terminates emigration of 
neural crest cells from the neural tube. Alternatively, DNMT3B may initially affect the 
maintenance of neural crest specifiers and affects on EMT genes may be the consequence 
of that. It is also possible that DNMT3B initially effects both EMT genes and neural crest 
specifier genes. It will be interesting to distinguish these possibilities by performing ChIP 
followed by qPCR to look at the occupancy of DNMT3B on the promoter regions of 
EMT genes and neural crest specifier genes.  
 
Taken together, we are just beginning to understand the contributions of epigenetic 
regulatory mechanisms in neural crest development. This is an important and open area for 
future investigations. Understanding the normal mechanisms of neural crest development 
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will contribute to the discovery of therapeutic treatments on birth defects, cancers, and 
other diseases associated with aberrant neural crest cells. 
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Figure. 1 
 
 
 
 
Figure. 2
 
Figure2. Preliminary data show loss of DNMT3A and 3B in neural crest cells results in 
premature formation of the trigeminal ganglion, especially the maxillo-mandibular lobe 
Figure1. Preliminary data indicates that 
DNMT3A is involved in olfactory placode 
formation. Knocking down DNMT3A during St.5 
leads to loss of olfactory tissues (bracket) at St.8.  
FITC inset shows DNMT3A MO was introduced 
to the left side of embryo, leaving the right side 
as internal control. 
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(circled in red). Embryos were electroporated with DNMT3A and 3B morpholino into the 
neural tube at St.8 and examined at St.13/14.  
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Abstract 
Glypicans are conserved cell surface heparan sulfate proteoglycans expressed in a 
spatiotemporally regulated manner in many developing tissues including the nervous 
system. Here, we show that Glypican-1 (GPC1) is expressed by trigeminal placode cells 
as they ingress and contribute to trigeminal sensory neurons in the chick embryo. Either 
expression of full-length or truncated GPC1 in vivo causes defects in trigeminal 
gangliogenesis in a manner that requires heparan sulfate side chains. This leads to either 
abnormal placodal differentiation or organization, respectively, with near complete loss 
of the ophthalmic (OpV) trigeminal ganglion in the most severe cases after 
overexpression of full-length GPC1. Interestingly, modulating GPC1 alters levels of 
endogenous Wnt signaling activity in the forming trigeminal ganglion, as indicated by 
Wnt reporter expression. Accordingly, GPC1 overexpression phenocopies Wnt inhibition 
in causing loss of OpV placodal neurons. Furthermore, increased Wnt activity rescues the 
effects of GPC1 overexpression. Taken together, these results suggest that appropriate 
levels of GPC1 are essential for proper regulation of canonical Wnt signaling during 
differentiation and organization of trigeminal placodal cells into ganglia. 
 
 
Introduction 
Glypicans (GPCs) are a conserved family of cell surface heparan sulfate 
proteoglycans (HSPGs) that modulate major signaling pathways during embryonic 
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development of fruit flies to mammals (Fico et al., 2007 and Filmus et al., 2008). 
Heparan sulfate side chains, attached to the core protein at conserved serine residues near 
the membrane anchored glycosyl-phosphatidylinositol (GPI) linkage, are thought to 
facilitate binding of growth factors and ligands, including Wingless/Wnt, Dpp/BMP, Fgf, 
and Hh, and are considered ligand carriers or coreceptors. Accordingly, functional 
perturbation of glypicans has been shown to cause significant defects in cell fate, cell 
movements, survival, and proliferation in mice, Xenopus laevis, Drosophila, and 
zebrafish ( Filmus and Song, 2000, De Cat and David, 2001, Lin, 2004 and Fico et al., 
2007). 
During vertebrate development, glypicans are expressed in a spatiotemporally 
regulated manner in the nervous system and other tissues (Niu et al., 1996, Saunders et al., 
1997, Litwack et al., 1998 and Luxardi et al., 2007). Their expression changes in 
pathological conditions, such as cancer. GPC3 and/or GPC1 are down-regulated in some 
ovarian cancer and mesothelioma cell lines (Lin et al., 1999 and Murthy et al., 2000) 
while upregulated in others (e.g., pancreatic tumors) (Kleeff et al., 1998, Filmus, 2001, 
Matsuda et al., 2001 and Su et al., 2006). Six glypican (GPC1–6) family members have 
been identified in mammals, two in Drosophila melanogaster (Dally and Dally-like), and 
two in Caenorhabiditis elegans (gpn-1 and lon-2) (Fico et al., 2007). Loss-of-function 
mutations in OCI-5/GPC3 in humans cause Simpson–Golabi–Behmel syndrome (SGBS), 
characterized by pre- and post-natal overgrowth, visceral and skeletal defects, and an 
increased risk of tumors (Pilia et al., 1996). A GPC3-deficient mouse model exhibits a 
similar phenotype (Cano-Gauci et al., 1999). Of the six glypicans in mammals, GPC1 is 
the most abundantly expressed in the developing brain, in both neuroepithelial precursors 
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and differentiated neurons ( Karthikeyan et al., 1994, Litwack et al., 
1994 and Litwack et al., 1998) and functions in neurogenesis of the central nervous 
system (Jen et al., 2009). However, its potential role in patterning and formation of the 
peripheral nervous system has yet to be explored. 
Here, we show that Glypican-1 is expressed by ectodermal and ingressing chick 
trigeminal placode cells at the time they differentiate into neurons and assemble into 
ganglia. Modulation of GPC1 levels by expression of full-length GPC1 or a truncated 
form that is thought to act in a dominant-negative fashion prevents placodal 
differentiation or proper ganglion formation, respectively, with particularly strong effects 
on the ophthalmic lobe. Consistent with studies showing that Wnt signaling is important 
for differentiation of ophthalmic trigeminal placodes (Lassiter et al., 2007 and Canning et 
al., 2008), we find that GPC1 regulates Wnt activity in OpV ganglion formation. The 
results suggest that proper levels of GPC1 are critical for appropriate modulation of 
canonical Wnt signaling for differentiation and assembly of trigeminal placodes into 
ganglia. 
 
Results 
 
Expression of Glypican-1 mRNA in the trigeminal placodes and other embryonic 
tissues during early chick development 
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As a first step in examining the possible developmental role of Glypican-1 
(GPC1), we first characterized its mRNA expression in the chick embryo at stages 9–18 
by whole mount in situ hybridization (Fig. 1 and data not shown). This corresponds to the 
time window of early trigeminal development starting from neural crest migration to 
ganglion condensation. No expression of GPC1 mRNA was noted in the trigeminal 
neural crest cells, derived from the midbrain and anterior hindbrain (rhombomeres 1 and 
2) levels of the neural tube, from stage 9 through gangliogenesis (Figs. 1A–C, F, L). 
Interestingly, we find that GPC1 is expressed by the presumptive trigeminal placodal 
ectoderm starting at approximately stage 12, coincident with the beginning of placodal 
differentiation and ingression but not earlier (Figs. 1C and D). GPC1 expression persists 
later as placodal cells assemble and condense into ganglion at stages 14–16 (Figs. 1F and 
L) and later at stage 18 (data not shown). GPC1 is expressed by both the ophthalmic 
(OpV) and maxillomandibular (MmV) placodes that form the trigeminal ganglion (Figs. 
1F and L). To confirm that these GPC1 expressing cells are in fact placode-derived, we 
labeled the placodal ectoderm with GFP by in ovo electroporation prior to placodal 
ingression. Embryos were then collected at later stages after placodal cells had begun to 
delaminate from the ectoderm. GPC1 expression was detected by in situ hybridization in 
the GFP-expressing placodal cells that had ingressed into the mesenchyme. Results show 
that all GFP-expressing placode-derived cells and discrete regions of the placodal 
ectoderm express GPC1 (Figs. 1G–J), while the interacting HNK-1-positive trigeminal 
neural crest cells do not. Not all placode-derived cells are GFP-labeled as the transfection 
of the ectodermal region was mosaic in some cases. 
In addition to placodal cells, GPC1 mRNA is expressed in other tissues. In 
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contrast to the midbrain neural crest, GPC1 is detected in the migrating hindbrain 
neural crest cells from rhombomeres 4 and 6 during migration at stage 12 (Figs. 1C and 
E), albeit transiently, being down-regulated by stage 14 (Figs. 1M and N). In the more 
posterior placodes, GPC1 is expressed in the epibranchial placodal ectoderm at stages 
14–16 (Figs. 1F, L, and M). The otic placode expresses GPC1 by stage 12, albeit weakly; 
by stage 14, its expression is strong in the invaginating and forming otic vesicle (Figs. 1F 
and M). Furthermore, GPC1 was weakly expressed in the forming cranial neural tube and 
notochord throughout these stages (Figs. 1A–M). The developing mesoderm and forming 
limb bud also express GPC1 (Fig. 1K). Expression is particularly dynamic in the 
developing somites. Through stages 9–18, the GPC1 mRNA appears to be expressed in a 
gradient in the presomitic mesoderm (PSM) highest at the newly forming somites and 
decreasing both rostrally toward the more anterior somites and caudally toward the tail 
(Figs. 1B and O). The expression patterns of GPC1 in the forming neural tube, somite, 
and limb are consistent with those described previously (Niu et al., 1996). This study 
analyzed developmental stages at stages7–12 and 20–25 but not the time window (stages 
13–18) or tissues involved in gangliogenesis as demonstrated here. 
The multiple tissue-specific expression patterns of GPC1 in the early developing 
chick embryo are consistent with possible roles for GPC1 patterning several different 
embryonic regions. The GPC1 expression in the trigeminal placodes at the time of 
neuronal differentiation and ganglion assembly, after specification, raises the intriguing 
possibility that GPC1 may have a role in regulating later events of trigeminal 
development. 
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Overexpression of Glypican-1 in placodes causes loss of trigeminal ganglia 
Glypicans are thought to act as ligand carriers or coreceptors for several major 
families of signaling molecules (Wnt, FGF, BMP, and Hh) (Lin, 2004 and Fico et al., 
2007); some of these have been implicated previously in trigeminal placode formation, 
most notably Wnts and Fgfs (Stark et al., 2000, Lassiter et al., 2007, Lassiter et al., 
2009 and Canning et al., 2008). Since modulation of glypican expression can 
differentially affect cellular behavior (Qiao et al., 2008) as well as the distribution and 
signaling of these growth factors (De Cat and David, 2001 and Hufnagel et al., 2006), we 
asked whether changing levels of GPC1 expression in the trigeminal placodes would also 
affect the signaling events required for normal gangliogenesis. To test this, we expressed 
higher levels of GPC1 in the trigeminal placodal tissue at or just prior to its endogenous 
expression in the placodes. Full-length chick GPC1 expression construct (cytopcig-FL-
GPC1), or the empty vector (cytopcig) as control, was introduced into the placodal 
ectoderm by in ovo electroporation at stages 8+ to 11 (5–14 ss [somites stage]) before 
placodal ingression and after expression of the earliest known trigeminal placode fate 
marker Pax3 mRNA which begins by 4 ss (Stark et al., 1997). Embryos with efficient 
electroporation of OpV and MmV lobes were analyzed at three time points corresponding 
to early ganglion formation (stages 15–16), after condensation (stages 17–18), and in the 
mature ganglion (stage 19). Neuronal components of the ganglion were analyzed by 
immunostaining with the neuronal marker, β-neurotubulin, TuJ1. Since neural crest cells 
differentiate into neurons much later (beginning at embryonic day 4; ~ stages 22–24) 
(D'Amico-Martel and Noden, 1980), only placodal cells express this marker at the stages 
examined, as shown previously by the colabeling of neuronal markers (TuJ1 and Islet1) 
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with GFP expressed by transfected placodal cells, whereas neural crest cells (Sox10- 
and HNK-1-positive) lack these markers (Shiau et al., 2008 and Shiau, 2009). 
The results show that overexpression of GPC1 in the placodal ectoderm causes a 
dramatic loss of the trigeminal ganglion, with nearly the entire OpV lobe missing in 
many cases (Fig. 2). The penetrance of this effect was categorized according to severity: 
“reduced” ganglia were clearly smaller by overall size in at least one lobe for all stages, 
whereas “severely reduced” were those that lost all or most of the OpV lobe at stages 15–
18 (Figs. 2A–F) or had both lobes markedly reduced at stage 19 (Fig. 2G–L). At stages 
15–18, 45% (n = 42) of the cases had markedly “reduced” ganglia, whereas ~ 10% were 
“severely reduced”. By stage 19, 25% (n = 12) were “reduced” and 8% were “severely 
reduced,” while no control GFP embryos showed a reduced phenotype (n = 23 at stages 
15–18, and n = 7 at stage 19) (Fig. 2M). The slight recovery with time may be caused by 
dilution of the construct over time, though we cannot rule out the possibility that there 
also may be some compensation by other mechanisms. The striking loss of trigeminal 
placodal neurons in the ganglia caused by alteration in GPC1 expression suggests that 
appropriate regulation of GPC1 expression is essential for gangliogenesis. 
 
GPC1 overexpression blocks proliferation and differentiation of the placodal 
ectoderm that leads to loss of ganglia 
The severely reduced ganglia caused by GPC1 overexpression prompted us to 
examine whether this is mediated by defects in cell survival and/or proliferation in the 
placodal tissue. To analyze changes in cell death, stage-matched FL-GPC1 and control 
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GFP embryos at stage 14 were sectioned and immunostained for active caspase-3 
(casp-3), which is a robust marker for apoptotic cells. Given that we can detect a 
phenotype as early as stages 15–16, embryos were examined at stage 14 which allows 
analysis of both ingression and coalescence of placodal neurons into ganglion. Only well-
transfected FL-GPC1 and control embryos were selected for analysis. We counted 
transfected GFP+ only and GFP+/casp-3+ double positive cells (apoptotic cells) in the 
placodal ectoderm as well as in the mesenchyme. The latter correspond to ingressing 
placode cells and those already in the forming ganglion. The percentage of dying cells 
was then calculated by dividing the number of GFP+/casp-3+ cells over the total number 
of GFP+ cells in each region (ectoderm versus mesenchyme). At least 10 serial sections 
through the trigeminal ganglion anlage were analyzed per n. Using this assay, our data 
show that there is no significant difference in levels of cell death between FL-GPC1 and 
control embryos (in the ectoderm, 2.2% ± 0.7% cell death in FL-GPC1, n = 4 compared 
with 0.85% ± 0.3% cell death in control cases, n = 4; p value = 0.22 using a two-tailed 
Student's t-test, Fig. 3A). No cell death was detected in ingressing placodal cells in the 
mesenchyme for either control or experimental cases. Taken together, data suggest that 
increased cell death cannot account for the loss of the OpV lobe. Interestingly, however, 
we found that transfected FL-GPC1, but not control, placodal ectoderm cells tended to 
abnormally cluster and formed clumps of cells in the ectoderm instead of forming a 
normally organized epithelial sheet from which placodes delaminate (Figs. 3B and C). 
We next analyzed whether proliferation in the placodal ectoderm is affected, 
using the same criteria and stages as for analysis of cell death. To determine the 
percentage of proliferating cells in the placodal tissue at stage 14, we briefly treated 
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electroporated embryos for 0.5 hour at the time of collection at stage 14 with 
bromodeoxyuridine (BrdU), an analog of thymidine that gets incorporated into dividing 
cells during the S phase. The short treatment provided a snapshot of all proliferating cells 
at the time point of collection, presumably within the 0.5 hour of treatment. At least six 
serial sections through the trigeminal ganglion anlage were counted and analyzed per n. 
Interestingly, BrdU analysis shows a significant reduction in proliferation in placodal 
ectoderm cells of FL-GPC1 embryos (12.9% ± 1.3% proliferation in FL-GPC1 (n = 6) 
versus 29.7% ± 2.7% in control (n = 4) cases; p value = 0.00061), with relatively normal 
levels of proliferation in the mesenchymally located placodal cells (8.0% ± 2.7% in FL-
GPC1 and 11.2% ± 3.8% in controls, p value = 0.54 using a two-tailed Student's t-test) 
(Figs. 3A and C). This difference between ectodermal and mesenchyme-residing cells 
suggests that GPC1 overexpression predominantly inhibits proliferation in the placodal 
ectoderm only. 
Since proliferation was significantly blocked in the placodal ectoderm and cell 
death was not significantly higher, the reduced ganglia phenotype may be due to a 
decrease in generation of placodal neurons in the surface ectoderm, leading to fewer of 
them ingressing to form ganglion. In support of this, we found significantly less 
ingression based on the average number of ectoderm-derived GFP + cells in the 
mesenchyme of the ganglion region analyzed in FL-GPC1 (36 ± 8 cells, n = 6) compared 
with controls (95 ± 17 cells, n = 4; p value = 0.015 using a two-tailed Student's t-test) 
(Fig. 3A). However, there was no significant difference in the average number of 
GFP+ in the ectoderm (300 ± 36 cells in FL-GPC1 versus 342 ± 5 cells in control GFP 
cases; p value = 0.38 using a two-tailed Student's t-test) (Fig. 3A). The numbers of 
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ingressed GFP+ cells and those in the ectoderm between control and experimental 
cases were counted from the same sections as those used for the BrdU analysis. 
The onset of GPC1 expression at the beginning of placodal differentiation in the 
ectoderm (Fig. 1D) is consistent with its possible role in differentiation of placodal cells. 
Differentiation of neurons appears to occur in the surface placodal ectoderm prior to 
ingression. This observation is based on the fact that placodal cells in the ectoderm 
already express neuronal markers (Islet1 and TuJ1) and all, if not most, of them that have 
ingressed express Islet1 and TuJ1 (as determined by labeling ingressing placodal cells 
using ectoderm electroporation with a GFP vector and examining whether all ectoderm-
derived GFP+ placodal cells express neuronal markers) (Shiau, 2009 and data not shown). 
In sections through the ganglion region of experimental and control embryos, we 
consistently observed fewer placodal neurons in the ectoderm and in the mesenchyme in 
FL-GPC1 embryos, particularly in the OpV region (Fig. 3D). GPC1 overexpression 
significantly inhibits proliferation in the ectoderm but not in ingressed placodal cells and 
we subsequently observed loss of placodal neurons. This suggests that appropriate 
regulation of cell division in the ectoderm may be crucial for placodal differentiation. 
Specification and commitment of the first placode cells to the ophthalmic (OpV) 
fate occurs by 8 ss (Stark et al., 1997 and Baker et al., 1999). We found no difference in 
the effect of overexpressing GPC1 on ganglion formation at the different stages of 
electroporation (5–14 ss), before or after 8 ss, suggesting that the effects of GPC1 
overexpression occur after initial fate specification. Furthermore, no changes were noted 
in expression of the early OpV placode fate marker Pax3 mRNA expression in FL-GPC1 
	   126	  
(n = 5/5) embryos compared with controls (n = 2) at stages 12–14 (data not shown). 
Taken together, the data suggest that the level of GPC1 expression is critical for 
the appropriate regulation of cell division in the placodal ectoderm, following their 
specification but prior to differentiation. GPC1 expression correlates with the onset of 
neuronal differentiation in the placode and its overexpression causes a specific 
proliferation defect in the differentiating ectoderm. This in turn leads to loss of placodal 
neurons, mostly those of the OpV lobe. Thus, problems with placodal differentiation 
likely explain the phenotype caused by GPC1 overexpression. 
 
Altering GPC1 expression causes ganglion disorganization and both truncated and 
full-length forms require heparan sulfate modification 
Several conserved domains of glypicans are important for their function, 
including the conserved heparan sulfate (HS) chains (long unbranched dissacharides) 
near the cell surface that attach to specific serine residues near the carboxyl terminus of 
the core protein and GPI membrane attachment site (De Cat and David, 2001) (see 
simplified schematic in Fig. 4A). Although a number of studies have highlighted the 
importance of HS modification for GPC function in regulation of several signaling 
pathways (including Wnt, Fgf, Hh, BMP) (Hacker et al., 2005 and Fico et al., 2007), they 
are not required in all cases (Gonzalez et al., 1998, Capurro et al., 2005, Kirkpatrick et al., 
2006 and Williams et al., 2010). GPI anchorage may be important for cell autonomous 
functions of GPC, such as being coreceptors for stabilizing ligand–receptor interaction or 
for regulating ligand levels by endocytosis. The GPI linkage also potentially plays a role 
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in post-translational modifications leading to cleavage of GPC to yield soluble forms 
of glypican that can affect distribution, spreading, or levels of ligand signaling (Fico et al., 
2007 and Gallet et al., 2008). 
To better define the mechanism by which full-length GPC1 (FL-GPC1) affects 
signaling during trigeminal development, we tested the functional requirement of HS 
modification and membrane anchoring. Three mutant GPC1 expression constructs were 
designed and tested in the trigeminal placodes: cytopcig–GPC1–ΔGPI which encodes a 
soluble truncated form of GPC1 where the GPI anchoring domain and remaining C-
terminal sequence are removed, cytopcig–GPC1–ΔHS that has a deletion of all three 
putative HS attachment sites near the carboxyl terminus, and cytopcig–GPC1–ΔGPI–
ΔHS which has deletion of both GPI anchoring and glycanation sites (Fig. 4B). We 
introduced these constructs into the trigeminal placodal ectoderm by in ovo 
electroporation during the same time window and in parallel with FL-GPC1 and control 
GFP as discussed above. Ganglia were scored at stages 15–19 for the reduced ganglia 
phenotype with only well-electroporated embryos selected for analysis. 
The results show that electroporation of either the mutant with deletion of the GPI 
anchoring, HS attachment sites or both fail to cause reduced ganglia observed with the 
wild type construct (Fig. 4C). To determine the size differences, we quantified the area of 
the ganglion using the ImageJ area function on outlines of TuJ1 stained ganglia. As 
expected, the size of the ganglion increases as it continues to grow from stage 15–16 to 
19 (Supplementary Fig. 1), albeit the area value at stages 15–16 is larger due to the fact 
that the cells are less condensed and more spread out. Compared with controls, the 
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ganglion area was, on average, over all stages, decreased by 39.4% ± 3.7% after 
electroporation with FL-GPC1. The area of FL-GPC1 electroporated embryos with 
phenotype (0.066 ± 0.017 mm2 at stages 15–16, 0.064 ± 0.006 mm2 at stage 17–18, 
0.11 ± 0.011 mm2 at stage 19) was markedly reduced compared with those electroporated 
with control GFP constructs (0.10 ± 0.009 mm2 at stages 15–16, 0.11 ± 0.005 mm2 at 
stages 17–18, 0.18 ± 0.012 mm2 at stage 19) or mutant forms of GPC1-expressing 
placodal ganglia at all stages (Supplementary Fig. 1). In contrast to that of FL-GPC1 
(49%, n = 53), expression of mutant GPC1 constructs in the trigeminal placodes resulted 
in significantly fewer ganglia of reduced size (GPC1–ΔGPI, 8.7% (n = 23); GPC1–ΔHS, 
9% (n = 11); GPC1–ΔGPI –HS, 5.6%, n = 18) (Supplementary Fig. 1). Control GFP 
ganglia exhibited no apparent ganglion reduction (n = 30) over all stages. 
Previous studies have shown that the truncated soluble form of GPC that lacks 
GPI membrane anchorage can act as a dominant-negative inhibitor (Zittermann et al., 
2009), presumably by competing with endogenous GPC for binding to signaling factors. 
Consistent with this idea, we found that expression of GPC1- ΔGPI did not cause the 
same level of reduced ganglia phenotype as that of FL-GPC1. Instead, it caused a distinct 
phenotype of disrupting ganglion morphology (26.1%, n = 23) at a significantly higher 
frequency than full-length construct (11.3%, n = 53); other mutant forms did not cause 
these effects (Supplementary Fig. 1). Furthermore, the subcellular localization of GPC1- 
ΔGPI is concentrated at or near the membrane. In contrast, the full-length construct is 
expressed in both the cytoplasm and on the membrane (Supplementary Fig. 2). This 
suggests that the GPC1– ΔGPI protein is properly processed for secretion to act in a 
soluble form. This is consistent with previous reports suggesting that a significant portion 
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of secreted glypicans lacking the GPI domain remain associated with the cell 
membrane due to electrostatic interactions ( Carey and Evans, 1989 and Gonzalez et al., 
1998). 
These cumulative results show that both the GPI anchoring and HS GAG chains 
are required for the effects observed after electroporation of FL-GPC1 into the placodal 
ectoderm. Furthermore, GPC1 may have a role in ganglion organization as expression of 
a putative secreted antagonist (GPC1–ΔGPI) leads to aberrant ganglia formation without 
reducing ganglion size. For either full-length or truncated GPC1 phenotype, we find that 
HS modification appears to be critical. 
 
Manipulating levels of GPC1 alters endogenous activity of Wnt signaling 
Given that glypicans interact with growth factors, it is intriguing to speculate that 
GPC1 may interact with Wnt signaling in the trigeminal placodes. Blocking canonical 
Wnt signaling inhibits placodal differentiation and OpV ganglion formation (Lassiter et 
al., 2007) in a fashion reminiscent of the effects observed with GPC1 overexpression. 
Furthermore, Wnts have been shown to bind and interact with glypican (De Cat and 
David, 2001, Ohkawara et al., 2003 and Baeg et al., 2004). Consistent with the possibility 
that Wnt signaling may be involved in various steps of trigeminal placode development, 
the trigeminal placode expresses Wnt receptors Frizzled-2 and -7, whereas several 
different Wnt ligands are expressed in the adjacent chick neural tube (Hollyday et al., 
1995, Marcelle et al., 1997 and Stark et al., 2000). 
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To address if there is a link between GPC1 and Wnt signaling in the 
trigeminal placodes, we tested whether increasing GPC1 expression or its mutant 
truncated form (GPC1–ΔGPI) would modulate endogenous levels of canonical Wnt 
signaling in vivo. To assay the activity of Wnt signaling, we used the RFP version of the 
TOPGAL Wnt reporter (DasGupta and Fuchs, 1999 and Lassiter et al., 2007) which 
drives RFP expression under the control of LEF/TCF consensus binding sites. Wnt 
signaling leads to stabilization and nuclear localization of β-catenin, which transactivates 
LEF/TCF transcription factors that bind to target LEF/TCF sequences to drive the 
expression of Wnt downstream genes and, in the case of the reporter, to drive RFP 
expression. The Wnt reporter was co-electroporated with the various glypican constructs: 
FL-GPC1 to overexpress GPC1 or GPC1–ΔGPI to block GPC1, or with empty GFP 
vector as control at stages 9–11. Electroporated embryos with broad transfection in the 
trigeminal region were collected at stages 14–16 for analysis. 
In control GFP embryos in which there is broad transfection of the entire 
trigeminal ganglia, we found Wnt signaling activity restricted to the OpV region. In 
general, few to no ganglion cells were RFP+ in the MmV (Fig. 5A). At early stage 14, 
Wnt reporter expression was observed in the dorsal ectoderm (including ectoderm 
overlying the dorsal neural tube) and OpV placodes at stage 14 (data not shown; Lassiter 
et al., 2007). RFP expression was restricted to the OpV lobe of the ganglion at stages 15–
16 and surrounding dorsal ectoderm (generally near the neural tube and above the OpV 
branch) (Fig. 5A). The area of cells in the OpV ganglion that expressed the RFP Wnt 
reporter appeared to increase over time, suggesting that the RFP expression is reflective 
of continuing addition of OpV placodal neurons to the ganglion and not merely from 
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residual RFP expression of placodal cells from earlier stages (Fig. 5A). 
Overexpression of GPC1 in the trigeminal placodal ectoderm caused a reduction in Wnt 
signaling activity in the OpV ganglion cells but not in the dorsal ectoderm cells external 
to the ganglion (22.2%, n = 18, Figs. 5A and B). The knockdown of Wnt signaling by 
GPC1 overexpression suggests that GPC1 may negatively modulate Wnt signaling. 
Further support for this idea stems from the finding that GPC1 gain-of-function caused 
loss of OpV ganglion, which is the same phenotype previously reported for inhibition of 
Wnt signaling (Lassiter et al., 2007). 
Consistent with the possibility that GPC1 modulates Wnt signaling, the truncated 
GPC1 construct (GPC1–ΔGPI) has the reciprocal effect of causing some expansion of the 
RFP Wnt reporter expression domain in the trigeminal ganglia (36%, n = 25, Figs. 5A 
and B). Not only was there an apparent increase in RFP expression in the OpV placodal 
ganglion, but, strikingly, there also was an expansion of RFP expression to the MmV 
domain near the border of the OpV lobe, as well as in sporadic placodal cells in the MmV 
ganglion distinct from controls (Fig. 5A). 
These results show that manipulating GPC1 expression or function causes a 
change in endogenous Wnt signaling levels, suggesting a potential role for Glypican-1 as 
a regulator of canonical Wnt signaling in trigeminal placodes. 
 
Activation of Wnt signaling reverses the effects of GPC1 overexpression but 
phenocopies effects of truncated GPC1 
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If the effects of GPC1 overexpression are mediated by reduced Wnt signaling, 
we predict that activation of Wnt signaling should rescue the ganglion loss. To test this, 
we used a dominant-active form of β-catenin (DA-βcat) in which the phosphorylation 
sites required for APC-mediated degradation are mutated, thus allowing β-catenin to 
constitutively activate Wnt target genes (Tetsu and McCormick, 1999 and Lassiter et al., 
2007). We co-electroporated DA-βcat with FL-GPC1 or control GFP in the trigeminal 
placodal ectoderm at stages 9–11 and examined formation of trigeminal placodal 
ganglion at stages 15–18 using TuJ1 antibody staining. The results show that activation 
of canonical Wnt signaling in these FL-GPC1 electroporated embryos eliminated the 
reduced ganglia phenotype observed after GPC1 overexpression (Fig. 6A). Furthermore, 
constitutive activation of Wnt-signaling alone (by DA-βcat plus GFP expression) in the 
placodal tissue produced disorganized ganglia (42.9%, n = 7) (Figs. 6A and B), similar to 
the effects of expressing the GPC1–ΔGPI construct. In addition, DA-βcat and FL-GPC1 
caused ganglion disorganization (33.3%, n = 6), perhaps due to abnormally high levels of 
Wnt signaling which not only reversed the inhibitory effects of GPC1 on Wnt signaling 
but also induced a gain-of-function phenotype. This effect is similar to expression of DA-
βcat alone. Thus, increased Wnt signaling through DA-βcat expression reversed the 
reduced ganglia phenotype of FL-GPC1, and the effects of constitutively activated Wnt 
signaling phenocopied that of the truncated GPC1 that may act in a dominant-negative 
manner. Taken together, these data suggest a potential negative regulation of Wnt 
signaling by GPC1 in the trigeminal placodes. GPCs are also known to interact with other 
signaling pathways ( Fico et al., 2007 and Filmus et al., 2008), raising the possibility that 
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GPC1 not only interact with Wnts but perhaps also with other signaling pathways 
functioning during placode differentiation. 
 
Discussion 
Our data provide novel insights into the expression and function of Glypican-1 as 
a potential modulator of Wnt signaling in the trigeminal placodes during neuronal 
differentiation and ganglion assembly. Wnt–glypican interactions in vivo have been best-
studied in the Drosophila wing imaginal disc ( Baeg and Perrimon, 2000, Franch-Marro 
et al., 2005, Gallet et al., 2008 and Yan et al., 2009) but are poorly understood in 
vertebrate development. Dally (division abnormally delayed), orthologue of vertebrate 
glypican 3/5, was found in a screen for defects in cell division patterning in the forming 
Drosophila CNS ( Nakato et al., 1995 and Filmus and Song, 2000). Dally mutants have 
delayed G2–M transition in dividing cells in the eye disc and lamina as well as defects in 
morphogenesis of adult tissues (i.e., the eye, antenna, wing, and genitalia) and in viability. 
Dally appears to act as a classical coreceptor that facilitates or enhances Wingless (Wg) 
signaling (Franch-Marro et al., 2005). In contrast, Dally-like (Dlp), the Drosophila 
orthologue of vertebrate GPC 1/2/4/6 (Filmus et al., 2008), has the opposite effect to 
Dally. It inhibits local but facilitates long-range Wnt/Wingless (Wg) signaling by 
transporting the signal to neighboring cells ( Franch-Marro et al., 2005, Gallet et al., 
2008 and Yan et al., 2009). Overexpression of GPC1 homologue Dlp causes reduced 
local Wg signaling and loss of imaginal disc tissue in a cell autonomous manner, whereas 
Dlp knockdown causes increased local Wg signaling ( Baeg and Perrimon, 
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2000 and Franch-Marro et al., 2005). 
Similar to the effects of Dlp, we observed a decrease in Wnt signaling with GPC1 
overexpression and an increase with the expression of a putative dominant-negative form 
of GPC1, GPC1–ΔGPI, which lacks the GPI anchorage, in the trigeminal placodal tissue. 
Our data show that the mutant GPC1–ΔGPI has the reciprocal effect to full-length GPC1 
by causing 1) an increase in Wnt signaling and 2) ganglion disorganization instead of a 
decrease in Wnt signaling and ganglion reduction as is the case after FL-GPC1 
transfection. This suggests that the truncated GPC1 form acts in a dominant-negative 
manner to disrupt normal GPC1 function or at least in a way that is distinct from the 
function of the full-length glycoprotein. In light of the alteration of endogenous Wnt 
signaling by manipulating GPC1 expression in the trigeminal placodes, the results 
suggest that GPC1 acts similarly to Dlp in that it can negatively regulate Wnt signaling. 
Similar negative regulation by GPC3 on canonical Wnt signaling has also been shown in 
mouse and culture studies (Song et al., 2005). 
The effects of altering GPC1 expression on endogenous Wnt signaling in 
trigeminal placodes appear to occur at later times during differentiation and assembly of 
placodal ganglia and not during Wnt's role in early ophthalmic (OpV) fate specification 
(Lassiter et al., 2007 and Canning et al., 2008). We found that GPC1 expression begins at 
~ stage 12 which is well after placode induction and that GPC1 overexpression does not 
affect expression of the early placode marker Pax3 but rather blocks later steps in 
neuronal differentiation. 
Interestingly, the most severe effect of GPC1 overexpression was the loss of OpV 
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placodal neurons, whereas MmV neurons were less affected. The OpV neurons are 
the same cells in which endogenous Wnt signaling is detected. We found that expression 
of the TOPGAL Wnt reporter was largely restricted to the OpV area and mostly absent 
from the MmV. These findings are consistent with the possibility that GPC1 regulates 
Wnt signaling in the forming OpV lobe of the trigeminal ganglion. 
How might GPC1 regulate Wnt signaling? In Drosophila, genetic evidence on 
Dally mutants clearly shows that Dally has a positive influence on Wg signaling (Lin and 
Perrimon, 1999, Fujise et al., 2001, Franch-Marro et al., 2005 and Han et al., 2005). 
However, the mechanism of Dlp is more complicated and several models have been 
proposed to explain its negative regulation. This includes cleavage of Dlp at the GPI 
anchor to create a secreted antagonist for Wg ligands (Kreuger et al., 2004), endocytosis 
of Dlp through its GPI anchor with Wg (as exchange of GPI anchor for a transmembrane 
domain blocks this function) (Gallet et al., 2008), functioning of Dlp as a competitor for 
ligand binding, and positive or negative action of Dlp based on the ratio of Wg, Wg 
receptor, and Dlp (Yan et al., 2009) or based on the modification of Dlp by cleavage 
(Kreuger et al., 2004). 
Here, we find that excess GPC1 expression inhibited Wnt signaling, similar to 
that of the Dlp, and expression of a mutant truncated GPC1 enhanced Wnt signaling. 
Distinct phenotypes, either loss or disorganization of the ganglion, were observed for the 
two types of perturbations respectively. One possibility is that GPC1 may act as a 
negative regulator of Wnt signaling in trigeminal placodes. Alternatively, GPC1 may act 
as both a negative and a positive regulator of Wnt such that different modes of GPC1 
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function (e.g., either as full-length or cleaved soluble form) or different levels of 
GPC1 expression might differentially influence Wnt signaling. For example, full-length 
GPC1 is capable of negatively regulating Wnt by reducing ligand levels by endocytosis 
via its GPI anchor, whereas truncated soluble GPC1 competes with full-length for ligand 
binding and therefore blocks endocytosis but promotes ligand distribution. Although the 
detailed mechanism is not yet known, it is clear from our findings that an appropriate 
level of GPC1 expression is required for normal formation of trigeminal placode-derived 
neurons, such that elevated GPC1 levels cause dramatic ganglion loss and lead to changes 
to endogenous Wnt activity. 
GPCs interact with several major signaling pathways in addition to Wnts. We 
have previously shown that the interaction between Slit1 from neural crest cells and its 
cognate receptor Robo2 on trigeminal placodes mediates proper assembly of the 
trigeminal ganglion in part through regulation of N-cadherin protein distribution on 
placodal neurons for ganglion aggregation (Shiau et al., 2008 and Shiau and Bronner-
Fraser, 2009). Direct interactions of heparan sulfate proteoglycans (HSPGs) with Slit 
have been suggested to be important for its function (Hussain et al., 2006, Fukuhara et al., 
2008 and Hohenester, 2008). Consistent with this, recombinant vertebrate Glypican-1 has 
been shown to bind specifically to Slit1 and Slit2 in rat brain extracts (Liang et al., 
1999 and Ronca et al., 2001). In light of this and the effect of disorganized ganglia 
caused by GPC1 inhibition using the soluble truncated form of GPC1, we cannot rule out 
the possibility that GPC1 may also regulate aspects of Slit-Robo signaling during 
trigeminal gangliogenesis. Similarly, GPC1 may affect Fgf signaling, which has been 
implicated in differentiation and ingression of trigeminal placodes (Canning et al., 
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2008 and Lassiter et al., 2009). Loss of Fgf signaling leads to failure of placodes to 
delaminate from the ectoderm and contribute to ganglion formation in the mesenchyme 
(Lassiter et al., 2009) similar to the effects we have shown of GPC1 overexpression. 
Regulation of Fgf signaling by glypicans has been demonstrated previously in other 
systems, including the mammalian brain and Drosophila tracheal morphogenesis ( Su et 
al., 2006, Yan and Lin, 2007 and Jen et al., 2009). 
In summary, we identify the heparan sulfate proteoglyan, GPC1, as a novel 
molecular player in trigeminal gangliogenesis. It is distinctively expressed by the 
trigeminal placodal ectoderm and placode-derived sensory neurons. Importantly, we 
show that it can act as a regulator of Wnt signaling during placodal differentiation and 
ganglion formation and that proper levels of GPC1 expression are essential for these 
processes in vivo. Our results represent an important entry point into dissecting the 
regulation of signaling mechanisms involved in early formation of the trigeminal sensory 
system in chick, potentially revealing how signaling is modulated at proper levels. 
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Materials and methods 
 
Embryos 
Fertilized chicken (Gallus gallus domesticus) eggs were obtained from local commercial 
sources and incubated at 37 °C to the desired stages. 
 
In situ hybridization 
cDNA plasmid obtained from BBSRC (ChickEST clone 418p2) was used to transcribe 
antisense riboprobe against chick Glypican-1. The plasmid was sequenced and found to 
contain the coding sequence of the chick Glypican-1 gene (NCBI accession number: 
XM_422590.1) corresponding to nucleotides 1233–2107. Whole-mount chick in situ 
hybridization was performed as described (Shiau et al., 2008). Embryos were imaged and 
subsequently sectioned at 12 µm. 
 
Immunohistochemistry 
Primary antibodies used were: anti-TuJ1 (Covance; 1:250), anti-HNK-1 (American Type 
Culture; 1:3–1:5), anti-GFP to recognize GFP signal after in situ hybridization 
(Molecular Probes; 1:150–1:250), anti-Islet1 (DSHB, clone 40.2D6; 1:150–1:250), and 
anti-active-caspase-3 (Promega; 1:150–250). Appropriate secondary antibodies against 
the subtype of the primary antibodies were conjugated to Alexa Fluor 488, 568, or 350 
dyes (Molecular Probes). Images were taken on a Zeiss Axioskop2 plus fluorescence 
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microscope, and processed using Adobe Photoshop CS3. 
 
In ovo electroporation of the trigeminal ectoderm 
Plasmid constructs were targeted to the presumptive trigeminal placodal ectoderm at the 
approximate axial level between the posterior forebrain and anterior hindbrain at 5 
somites stage (stage 8+) up to stage 11. Immediately after injection, platinum electrodes 
were placed vertically across the chick embryo delivering current pulses of 5 × 8 V in 
50 ms at 100 ms intervals as described (Shiau et al., 2008). Targeting DNA to the 
ectoderm resulted in transfection of the trigeminal placodes in the ectoderm and 
subsequently placode-derived cells that detach from the ectoderm and migrate into the 
ganglion anlage. The operated eggs were sealed and incubated at 37 °C for later analysis. 
Incubation times were ~ 16–24 hours to reach stages 13–14, ~ 24–36 hours to reach 
stages 15–16, ~ 40–48 hours to reach stages 17–18, and ~ 50–60 hours to reach stage 19. 
 
Plasmid constructs 
Full-length chick Glypican-1 cDNA (clone CS5) was isolated from a 4- to 12-somite 
stage chick macroarray library (Gammill and Bronner-Fraser, 2002). To create cytopcig-
FL-GPC1, the full-length coding sequence (1.65 kb) was amplified from the library clone 
CS5 by PCR using forward and reverse primers corresponding to the coding sequence 
with flanking XhoI and ClaI site, respectively. Gene fragment was directionally inserted 
into the cytopcig vector (Shiau et al., 2008) at the XhoI/ClaI sites. Three mutant GPC1 
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constructs were made by a single-step or fusion PCR amplification off the full-length 
sequence, and a modified gene fragment was directionally cloned into the XhoI and ClaI 
sites in the cytopcig vector. These are 1) cytopcig–GPC1–GPI, which encodes the first 
517 amino acids (1.55 kb) with a premature stop codon which eliminates the GPI-
anchoring domain, 2) cytopcig–GPC1–ΔHS, which has a 18-bp deletion that spans a 
coding region of six residues, SGSGSG (483–488 aa), containing three tandemly 
positioned putative glycosaminoglycan (GAG) attachment sites (serine residues 483, 485, 
487) based on sequence annotation in UniProtKB for chick GPC1 protein (accession 
P50593), and 3) cytopcig–GPC1–ΔGPI–ΔHS, which has deletions of both the GPI-
anchor domain and the putative HS sites. Two versions of full-length and mutant 
constructs were made: one without myc–tag fusion and one with a 6× myc–tag inserted at 
ClaI/EcoRV sites in frame with the coding sequence at the C-terminus, which was used 
to validate protein expression of the constructs. Both versions were tested and determined 
to give the same effects on ganglion development, albeit FL-GPC1 was more potent 
without the myc–tag. Thus, most experiments with the full-length and mutant expressions 
were conducted with the construct lacking the myc–tag. Dominant-active β-catenin 
construct was made in the pCIG vector with IRES nuclear localized GFP as previously 
described ( Megason and McMahon, 2002 and Lassiter et al., 2007), and RFP-Wnt 
reporter (also named pTOP-nDSRed2) (gift from Dr. Andy Groves [Lassiter et al., 2007]) 
was a modified version of the TOPGAL construct (DasGupta and Fuchs, 1999) where the 
reporter gene was replaced with RFP. 
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BrdU treatment 
Electroporated embryos were screened and selected for broad GFP expression in the 
trigeminal region at stage 14 for both control and experimental cases. Each embryo was 
explanted into an individual well and treated with 0.1 mM BrdU in Ringer's solution at 
37 °C for 30 minutes. Embryos were then fixed in 4% paraformaldehyde overnight at 
4 °C, washed in PBS, incubated in 2N HCl in PBS for 30 minutes, followed by 0.1 M 
perboric acid (H3BO4) for 10 minutes, washed in PBS several times, and processed for 
cryosectioning and immunostaining with the mouse anti-BrdU (Sigma, B2531; 1:150–
1:250). 
 
Quantification of the area of trigeminal ganglion 
An outline of the ganglion as marked by TuJ1 staining was made by the freehand 
selection tool on whole mount grayscale fluorescent images in the ImageJ software. All 
images were taken with the same setup using a 5× objective on the Zeiss Axioskop2 plus 
microscope and at the same image size, with the entire ganglion in focus. The area of the 
ganglion outline was determined by the area measurement function in ImageJ with the 
scale calibrated to the actual length. 
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Figures and Figure Legends 
Figure1 
 
Fig. 1. Expression of Glypican-1 mRNA in the early chick embryo. (A) Stage 9 and (B) 
stage 10 embryos showing GPC1 mRNA expression in the neural tube (arrow) but not in 
the migrating midbrain neural crest cells, and in the presomitic mesoderm (PSM) and the 
most caudal somites in a gradient fashion, high (black arrowhead) to low (gray 
arrowhead) expression. (C) Stage 12 embryo showing onset of GPC1 expression in the 
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forming trigeminal placodes (arrow) and migrating hindbrain neural crest cells at 
rhombomere 4 (r4) (gray arrow). Cross sections as indicated in C showing GPC1 
expression in (D) placodal ectoderm and spurs of ingressing placodal cells (arrow) (E) 
and hindbrain migratory neural crest cells (arrow). (F) GPC1 expression in the 
ophthalmic (OpV) and maxillo-mandibular (MmV) placodes of the forming trigeminal 
ganglion and in the otic vesicle at stage 14. (G) Cross section through the OpV region of 
F showing GPC1 expression in the placodal ectoderm and ingressing placodes (dotted 
box) and weakly in the neural tube. (H–J) Higher magnification of the dotted box in G 
showing GFP-labeled ingressing trigeminal placodal cells express GPC1 (arrows) but 
HNK-1 expressing neural crest cells do not. (K) Stage 16 embryo showing expression in 
the forming limb bud (arrowhead). (L) GPC1 expression persists in the OpV and MmV 
placodes and the otic vesicle. (M–N) Cross section of F showing GPC1 expression in the 
otic placode, epibranchial ectoderm (arrow), and r4 HNK-1-expressing hindbrain neural 
crest cells (arrowhead). (O) GPC1 expression persists in the PSM (arrowhead) and newly 
formed somites at stage 14. OpV, ophthalmic; MmV, maxillo-mandibular; nt, neural 
tube; ot, otic; no, notochord; nf, neural folds. 
  
	   144	  
Figure2 
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Fig. 2. Increased Glypican-1 expression in the placodal ectoderm leads to significant 
loss of placodal ganglia. Ectoderm-electroporated embryos analyzed at stage 17 showing 
(A) normal trigeminal ganglion formation with control GFP and (B and C) reduced or 
severely reduced ganglia with full-length GPC1 (FL-GPC1). Color overlay images show 
area of transfection by GFP expression in green and placodal neurons by TuJ1 antibody 
staining in red. (D–F) Single-channel images of TuJ1 of the above overlay images in A–
C; insets, GFP expression only. Ganglia assessed at stage 19 showing (G) normal 
ganglion in controls but (H and I) markedly reduced ganglia in FL-GPC1 embryos. (J–L) 
Single channel images of TuJ1 of G-I and insets show GFP expression of the color 
overlay. (M) Histogram showing frequency of reduced and severely reduced ganglia 
phenotypes. n = number of ganglia analyzed. 
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Figure3 
 
Fig. 3. GPC1 overexpression blocks cell proliferation and differentiation of the placodal 
ectoderm, but does not induce significant cell death. (A) Top, histogram showing no 
significant difference in cell death level between control GFP and FL-GPC1 in the 
ectoderm. Bottom, graph showing that, compared with controls, FL-GPC1 embryos had 
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significantly reduced percentage of proliferation in the placodal ectoderm and 
decreased total number of ingressing placodal cells. Dotted line marks the 50% level. 
Bars indicate s.e.m. n = the number of forming ganglia analyzed. (B) Cross sections 
through the OpV region at stage 15 showing few caspase-3 positive transfected cells in 
the ectoderm (arrow) and none in the mesenchyme (arrowhead, which are ingressed 
placodal cells) in both control GFP and FL-GPC1 embryos. FL-GPC1 transfected ganglia 
had regions of strikingly aberrant clustering of cells in the ectoderm distinct from 
controls (asterisk). (C) Electroporated embryos collected at stage 14 were treated with a 
short half hour pulse of BrdU to detect S-phase mitotic cells at the time of analysis. 
Frontal plane sections at stage 14 showing (top panels) many proliferating cells in the 
ectoderm in control (BrdU+, arrows). By contrast, (bottom panels) most FL-GPC1 
transfected ectodermal cells are non-mitotic (BrdU− and GFP +, arrows) and tend to 
cluster (asterisk). Most ingressed placodal cells in both control and FL-GPC1 
transfections were not mitotic (BrdU−, arrowheads) though occasionally a very small 
number of them are (red arrowhead, top panel). (D) Frontal plane sections through the 
ganglion as shown by the dotted line in the schematic (left) showing strikingly less 
placodal neurons (Islet1+/TuJ1+) particularly in the OpV region in FL-GPC1 embryo 
(arrows) compared with control. OpV, ophthalmic; MmV, maxillo-mandibular. 
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Figure 4 
 
Fig. 4. Truncated form of GPC1 causes disorganization of ganglion distinct from full-
length, and both full-length and truncated forms require the putative heparan sulfate 
glycosaminoglycan (GAG) attachment sites for function. (A) Simplified schematic of 
glypican shows its heparan sulfate (HS) side chains near the cell surface and GPI 
membrane anchor acting as a potential coreceptor or ligand carrier for signaling receptors. 
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(B) Diagram showing the domains of the full-length GPC1 (FL-GPC1) and the 
modifications made on the mutant forms of GPC1. Since HS attachment sites are known 
to localize near the membrane anchor of glypicans, all predicted HS attachment sites at 
the C-terminus for chick GPC1 in the UniProtKB database were excised in HS deletion 
constructs; there remains only one predicted site located near the N-terminus (asterisk). 
(C) Representative images showing stage 18 placodal ganglia (Islet1+/TuJ1+) 
electroporated with mutant GPC1 constructs with deletions of HS or both GPI and HS 
domains that were generally normal and similar to controls. By contrast, GPC1-ΔGPI 
transfected placodal ganglia were normally sized but disorganized. 
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Figure5 
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Fig. 5. Changes to GPC1 expression alters endogenous Wnt signaling activity. (A) 
Top row, color overlay images showing trigeminal ganglia in whole mount chick 
embryos at stages 15–16 after electroporation with control GFP, FL-GPC1, or GPC1–
ΔGPI constructs. GFP in green showing area of transfection (also shown in second row 
panels). TuJ1 in blue showing placodal neurons (also shown in third row panels). RFP 
version of TOPGAL Wnt reporter expression in red showing endogenous activity of Wnt 
signaling (also shown in fourth row panels). Outline of the trigeminal ganglion is 
demarcated by the dotted lines. Fourth row panels, controls show Wnt reporter expression 
restricted to the OpV region at stages 15 and 16 with generally absence of reporter in the 
MmV region (asterisk), albeit occasionally one or a few cells were Wnt-Rep+. Reporter 
expression in the OpV appears to increase over time. By contrast, FL-GPC1 expressing 
placodal ganglia had markedly reduced Wnt reporter expression in the OpV region, and 
similar to controls, had generally little to no reporter expression in the MmV region 
(lower asterisk). Conversely, expression of GPC1-ΔGPI led to more expression of Wnt 
reporter in the OpV (arrowhead) and expansion of reporter expression into the MmV 
region in more cells, though sparsely (arrows). (B) Histogram showing percentages of 
cases of reduction of Wnt reporter expression in the OpV and of expansion of Wnt 
reporter expression, which means an increase in reporter expression in OpV as well as 
expression in greater number of cells in MmV, after electroporation with control GFP, 
FL-GPC1, or GPC1–ΔGPI. n = number of ganglia analyzed. Wnt-Rep, Wnt reporter; 
OpV, ophthalmic; MmV, maxillo-mandibular. 
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Figure6 
 
Fig. 6. Induced activation of Wnt signaling phenocopies the effects of truncated GPC1 
and reverses the effects of GPC1 overexpression. (A) Coexpression of a dominant-active 
form of β-catenin (DA-βcat) with FL-GPC1 in the placodal tissue suppresses the reduced 
ganglia phenotype. Both control and experimental expressions of DA-βcat with control 
GFP or FL-GPC1, respectively, led to some disorganized integration of placodal cells 
into ganglia. GFP in green showing area of transfection and TuJ1 in blue showing 
placodal neurons. (B) Histogram showing frequency of phenotypes: “reduced” means 
decreased in overall ganglion size and “disorganized” means aberrant integration of 
placodal cells. n represents number of ganglia analyzed.  
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Supplementary Figure 1  
 
Supplementary Figure 1 Measurement of ganglia sizes shows dramatic reduction 
after expression of full-length but not mutant forms of GPC1. (A) Graph showing the 
area of trigeminal ganglia does not show significant differences between control and 
mutant GPC1 electroporated embryos through the different stages of analysis (stages 15 – 
19).  Separate plots were made for FL-GPC1 electroporated ganglia, also shown in Fig. 2, 
that were either normally or reduced sized in order to show the dramatic area reduction in 
“reduced” phenotype cases. Bars show s.e.m. (B) Histogram showing frequency of the 
two types of phenotypes detected over all analyzed stages 15–19: “reduction” means 
overall ganglion size is reduced and “disorganized” means aberrant integration of 
placodal cells but with generally normal ganglion size.  GPC1 over-expression by FL-
GPC1 caused a significant percentage of reduced ganglia (accounting for both “reduced” 
and “severely reduced” phenotypes as shown in Fig. 2), while GPC1 inhibition by GPC1-
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ΔGPI led to a high percentage of disorganized ganglia. The reduced ganglia 
phenotype is largely not detected with expression of any mutant GPC1 construct.   
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Supplementary Figure2 
 
Supplementary Figure 2 Subcellular localization of FL-GPC1 and GPC1-ΔGPI 
proteins by myc-tag detection. Chick embryos transfected by in ovo electroporation 
targeting the trigeminal placodal tissue with either the cytopcig-FL-GPC1-6xmyc or 
cytopcig- GPC1-ΔGPI-6xmyc construct were selected for high cytoplasmic GFP reporter 
expression and collected for section analysis at stage 14.  Sections through the trigeminal 
region show (A-D) GFP positive transfected ectodermal and placodal cells expressing 
FL-GPC1-6xmyc protein as shown by the myc tag in red.  (B-D) Higher magnification of 
the dotted box region in A showing expression of FL-GPC1 myc fusion protein localized 
to both the cytoplasm and the cell membrane (arrows). (E-H) By contrast, GPC1-ΔGPI-
6xmyc protein expression is more highly concentrated at or near the placodal cell 
membrane than FL-GPC1 (arrows), and in some cells is undetectable in the cytoplasm 
(top arrow).  
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